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1. ABSTRACT 
 
Glioblastoma (GBM) is the most common and most 
malignant brain tumor in humans. The prognosis is poor 
since GBM is highly-resistant to therapy and possesses a 
strong migratory and invasive potential, making complete 
surgical resection impossible. Previous work demonstrated 
that Carboxypeptidase E (CPE), originally identified as a 
neuropeptide processing enzyme, is secreted by a subcohort 
of malignant glioma and, if overexpressed in glioma cells, 
exerts anti-migratory, but pro-proliferative activity, 
suggesting that CPE might be a ‘‘Go or Grow’’ switch 
factor. Here we describe CPE mainly as an anti-migratory 
protein in glioma cells and we aim in deciphering the 
mechanism by which CPE modulates glioma cell behavior. 
Using transcriptome analyses, followed by Ingenuity 
Pathway Analyses (IPA) and investigation of several 
signaling cascades, we found that in CPE-overexpressing 
cells a variety of motility-associated mRNAs and miRNAs 
were differentially regulated and connected to motility-
associated networks including FAK, PAK, CDC42, 
integrin, STAT3, TGF-β as well as ERK1/2. In particular 
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SNAI2/SLUG, a transcription factor known to induce 
tumor cell motility and metastasis, was downregulated. 
Matrix-Metallo-Proteases (MMP) as well as MMP-activity 
inducing factors, all necessary for glioma cell invasion, 
were reduced in CPE-overexpressing cells. SNAI2/SLUG 
expression was regulated via ERK1/2 since inhibition of 
ERK1/2 activation abolished CPE-mediated SLUG 
downregulation and reduction of cell migration. Moreover, 
we showed a synergistic effect of CPE overexpression in 
combination with standard glioma therapy (Temozolomide 
and radiation) in the clonogenic survival of GBM cells. In 
vivo, the anti-migratory capacity of CPE translated in 
prolonged survival of mice bearing CPE-overexpressing 
tumors. These data help to understand the role of migration 
in glioma aggressiveness and how CPE is involved in this 
process.   
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2. INTRODUCTION 
2.1 GLIOBLASTOMA 
2.1.1 General features 
Gliomas are a common adult central nervous system (CNS) 
tumor and they account for the 77% of primary brain 
tumors diagnosed every year worldwide, which are more 
than 250000 new cases [1]. Nearly 60% of high-grade 
gliomas are glioblastoma (GBM) and incidence has been 
increasing in the last decades up to 3,5 new cases of GBM 
per 100000 inhabitants in western countries every year [2]. 
GBM is clearly the most frequent, but unfortunately also 
the most aggressive and malignant brain tumor. 
Symptomatology in glioma patients is distinctly different 
from other cancer patients because of the neurological 
symptoms like paresis, visual-perception deficits, sensory 
loss, cognitive deficits or seizures, and in some cases 
changes in personality and behavior have been reported [3, 
4]. GBM are called glioblastoma multiforme due to the 
high heterogeneity of cells in the tumor and among 
different GBMs. Because of that, classification is in 
constant evolution due to the discovery of new mutations 
and refined diagnostic tools, especially for molecular 
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features. The WHO (World Health Organization) recently 
felt the need to update the previous glioma classification 
from 2007 [5]. Former classification was mainly based on 
histological characteristics of the tumor and as a result 4 
different grades were individuated (I-IV), with the lower 
grades supposed to be less aggressive and have a better 
outcome and higher grades to have a poor prognosis. The 
updates on glioma classification will be presented in detail 
later. GBM presents characteristics which makes it the 
most malignant brain tumor. Indeed, because of the highly 
infiltrative growth, complete surgical resection is 
impossible and recurrence is inevitable. If untreated, GBM 
leads to death in 3 to 6 months, and even providing the best 
therapy options, which includes irradiation and 
chemotherapy after surgery, median patient survival 
increases to only 15 months [6]. Despite the efforts in the 
last decades in GBM research, alternative treatment options 
or adjuvants applied to standard therapy are urgently 
needed. 
2.1.2 Glioma classification 
The World Health Organization (WHO) redefined the 
classification of tumors of the central nervous system in 
2016 [7], integrating the histological criteria used in the 
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previous WHO classification 2007 [5] with more updated 
molecular parameters. 
The class of brain tumor relevant for this work is the 
diffuse glioma (Table 2.1.1), which includes all diffusely 
infiltrating gliomas, whether they developed from cells of 
astrocytic or oligodendroglial origin. They are divided in 
the WHO grade II and grade III astrocytic tumors, the 
grade II and III oligodendrogliomas and the grade IV 
GBM. The higher grade indicates a more malignant and 
aggressive phenotype, as in the former classification. They 
are grouped according to their growth pattern and behavior 
and the subclasses are based on the shared genetic driver 
mutations in the isocitrate-dehydrogenase (IDH)1 and 
IDH2 genes. In the past the status of these genes, mutated 
(mut) or wild-type (wt), was mainly used in diagnosis to 
define whether a GBM was a primary de novo tumor (IDH 
wt) or secondary (IDH mut), arising from a lower grade 
glioma [8]. Moreover a third class of GBM is called GBM 
NOS in case the status of IDH genes cannot be defined. An 
additional variant of GBM, called epithelioid glioblastoma, 
has been introduced. It joins giant cell glioblastoma and 
gliosarcoma under the class of IDH-wildtype GBM. Other 
key mutations or genetic alterations necessary for the 
classification of diffuse gliomas are the 1p/19q codeletion, 
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which is prognostically favourable, and K27M mutations in 
the histone 3 (H3) gene, found in midline diffuse glioma 
[7]. 
 
 
Table 2.1.1 2016 WHO classification of diffuse glioma. 
Table depicted from [7], representing the 2016 WHO 
classification of tumors of the CNS. 
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Nevertheless the histological features of diffuse gliomas 
still play an important role in their classification. In 
particular GBM are characterized by hypercellularity, 
pronounced angiogenesis, high proliferation rate, 
infiltrative growth, nuclear atypia and central necrosis 
(Figure 2.1.1). A simplified schema for diffuse glioma 
classification and grading is shown in Figure 2.1.2. 
 
 
Figure 2.1.1 Hematoxylin/eosin (HE) stain of a section 
of a GBM [9].  
Arrows indicate blood vessels, asterisks indicate necrotic 
areas surrounded by pseudopalisading cells. 
 
 
*
*
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Figure 2.1.2 Schematic representation of diffuse glioma 
classification. Grades indicate malignancy, 
*: characteristic, but not required for diagnosis, revisited 
from [7].  
  
Genetic test not done
or inconclusive
ATRX loss*
TP53 mutation*
Histology Astrocytoma Oligoastrocytoma Oligodendroglioma Glioblastoma 
IDH status IDH mutant IDH wild type IDH mutant IDH wild type
1p/19q codeletion
1p/19q and 
other genetic
parameters
Diffuse astrocytoma, 
IDH mutant, grade II/III
Oligodendroglioma, 
IDH mutant and
1p/19q codeleted,
grade II/III
Diffuse astrocytoma, 
IDH wild type, grade II/III
Oligodendroglioma, 
NOS, grade II/III
Glioblastoma, 
IDH mutant, 
grade IV
Glioblastoma, 
IDH wild type,
grade IV
Diffuse astrocytoma, NOS, grade II/III
Oligodendroglioma,  NOS, grade II/III
Oligoastrocytoma, NOS, grade II/III
Glioblastoma, NOS, grade IV
22 
 
In parallel with the update in CNS tumor classification, 
several studies have been performed in the last years to 
divide gliomas, especially GBM, in different subtypes 
according to common mutations and phenotypes. The most 
important studies were performed by Philips [10] and 
Verhaak [11] and four subtypes have been specified: 
proneural, classical, mesenchymal and neural (Figure 
2.1.3).  
The proneural (PN) subtype is defined by a better 
prognosis and expression of genes associated with healthy 
brain tissue and neurogenesis. The other subtypes differ 
from the PN subtype primarily because of the poor 
prognosis and a shorter patient survival. Tumors belonging 
to the mesenchymal (Mes) subtype exhibit indications of 
increased migration, angiogenesis and enhanced 
microvascular proliferation. The proliferative (Prolif) 
subtype, as indicated by its name, is characterized by a high 
proliferation rate, revealed by a high percentage of tumor 
cells active in cell division. This last subtype is then 
divided in neural and classical subtypes, because of the 
presence in the neural group signature of genes 
differentially expressed by neurons. 
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Figure 2.1.3 Transcriptional subtypes of GBM based on 
the classification defined by Phillips and Verhaak [12]. 
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2.1.3 Molecular mechanisms involved in GBM 
malignancy 
The main reason for the high malignancy of GBM is the 
inevitable recurrence due to the highly infiltrative 
phenotype and the impossibility to remove all the tumor 
cells completely during surgical resection. Besides that, 
GBM malignancy is also accompanied by other pro-
tumorigenic aberration that enhance cell growth, help to 
overcome cell death or anti-tumor immune responses or 
that leads to therapy resistance.  
2.1.3.1 Proliferation and cell cycle 
As proved by histology, GBM cells present a high 
proliferation rate which is often caused by mutations or 
genetic alterations leading to uncontrolled proliferation and 
malfunctioning of the cell cycle key check-points. 
About 50% of GBM present perturbation of the epidermal 
growth factor receptor (EGFR), represented by an 
amplification or the presence of a constitutive active 
variant (EGFR vIII). The latter is a product of a deletion of 
exon2-7 in the EGFR gene, leading to the expression of a 
truncated version of EGFR, lacking a part of the extra 
cellular domain. In both cases activation of pro-
proliferative signaling cascades like the mitogen-activated 
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protein kinase (MAPK)/extracellular signal-regulated 
kinase (ERK) pathway occurs [13]. The classical activation 
of the EGFR signaling cascade starts with the extracellular 
ligand EGF, binding to its receptor on the cell surface. This 
interaction leads to an auto-phosphorylation of EGFR, and 
via interaction with scaffold proteins like growth factor 
receptor-bound protein 2 (GRB2) and SOS Ras/Rac 
guanine nucleotide exchange factor (SOS), allows the 
activation of the small GTP binding protein (RAS), 
subsequently inducing the phosphorylation and activation 
of a cascade of kinases: RAF/MEKK/MEK/ERK. 
Ultimately, this activation leads to the activation of  
transcription factors and finally alters gene expression of 
cell cycle control genes [14]. 
Other common mutations in GBM which lead to an 
uncontrolled cell cycle are inactivating mutations of tumor 
suppressors such as tumor protein p53 (TP53) or 
retinoblastoma-protein (RB), or mutations of their 
regulators. One example is the gene INK4A, which 
encodes two different proteins due to the presence of 
alternative splicing sites, cyclin dependent kinase inhibitor 
2A (CDKN2A-p14
ARF
 and CDKN2A-p16
INK4a 
). Binding of 
the first one with double minute 2 (MDM2) leads to correct 
activation of p53. On the other hand, CDKN2A-p16
INK4a 
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negatively regulates cyclin dependent kinase 4 (CDK4), 
which controls the activity of RB. Therefore a 
simultaneous inactivation of CDKN2A-p14
ARF
 and 
CDKN2A-p16
INK4a 
causes deregulation of both RB and p53 
pathways [15].  
Another tumor suppressor involved in GBM gliomagenesis 
is phosphatase and tensin homologue deleted on 
chromosome 10 (PTEN), which negatively regulates 
protein kinase B (AKT) pathway. Loss of heterozygosis 
(LOH) at the 10q23.3 locus or gene mutations (15% to 
40%) leads to the loss of function of PTEN, a constitutively 
activated signaling pathway and, besides other pro-
tumorigenic effects, to uncontrolled cell proliferation [15]. 
2.1.3.2 Apoptosis and cell death 
Many chemotherapy approaches as well as tumor 
irradiation used for GBM treatment are ineffective due to 
the fact that GBM cells developed several mechanisms to 
overcome cell death. For example, a variety of proteins that 
are necessary for the induction of apoptosis by extrinsic or 
intrinsic stimuli, are differentially expressed in GBM. 
Expression of death receptor molecules such as Fas cell 
surface death receptor (FAS) or TNF-related apoptosis 
inducing ligand (TRAIL) are often downregulated while 
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the expression of decoy receptors that compete for death 
ligand binding can be upregulated. Moreover, caspase 
activation might be blocked by loss of function mutations 
in these protein or by overexpression of anti-apoptotic 
proteins like B-cell lymphoma 2 (BCL-2), B-cell 
lymphoma-extra large (BCL-XL), baculoviral IAP repeat 
containing 5 (BIRC5, survivin) or X-linked inhibitor of 
apoptosis (XIAP) (for review see [16]). 
2.1.3.3 Migration and invasion 
As already specified above, GBM is characterized by a 
strong infiltrative growth, which is the result of the 
activation of pro-migratory and pro-invasive pathways, 
often accompanied by the rearrangement of the 
cytoskeleton. Different components of the plasma 
membrane, like integrins, can also regulate motility-
associated signaling cascades, and altered integrin 
expression can be correlated to cancer progression and 
malignancy. Integrins are proteins that anchor cells to the 
extracellular matrix (ECM), and integrin subtype 
expression is different in malignant versus non-neoplastic 
cells. For example, integrin v3 is abundantly expressed in 
high grade brain tumors [17].  
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Focal adhesion kinase (FAK) is a non-receptor tyrosine 
kinase involved in signal transduction pathways activated 
by integrin-mediated cell adhesion and by growth factor 
receptors [18]. It modulates several processes, including 
migration and invasion. Perturbation of FAK activity 
impairs GBM cell migration [19].  
The small Rho-GTPases (ras homolog family member A 
RHOA, ras-related C3 botulinum toxin substrate 1 RAC1, 
cell division cycle 42 CDC42) and their effectors, including 
p21 activated kinase 1 (PAK), play an important role in 
GBM migration and invasion by modulting filopodia and 
actin stress fiber formation in glioma cells, thus leading to 
a more migratory and invasive phenotype [20].  
Other migration-associated pathways involve the signal 
transducer and activator of transcription 3 (STAT3) and 
the transforming growth factor β (TGFβ). In response to 
growth factors or cytokines, STAT3 is phosphorylated by 
receptor-associated Janus kinase (JAK). This event leads 
to STAT3 dimerization and its translocation into the 
nucleus where it can act as a transcription factor [21]. 
STAT3 activation is associated with a more malignant 
glioma phenotype and poor clinical outcome [22]. 
Moreover, STAT3 silencing inhibits glioma single cell 
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inﬁltration and reduces the expression of many motility-
associated genes [23].  
TGFβ binds to its specific receptor (TGFβRI) leading to the 
recruitment and phosphorylation of TGFβRII, which can in 
turn phosphorylates mothers against DPP homolog 2/3 
(SMAD2/3). Phosphorylated SMAD2/3 form a heterodimer 
with SMAD4. This complex shifts into the nucleus and 
modulates genes transcription [24]. TGFβ promotes, among 
others, activation of matrix metalloproteinases (MMPs) 
[25], necessary for ECM remodeling during tumor cell 
invasion. In particular, overexpression of MMP-2 and 
MMP-9 correlates with high grade glioma [26]. 
The exact mechanisms by which tumor cells invade the 
surrounding healthy brain tissue are still under 
investigation. Transcription factors like zinc finger E-box 
binding homeobox (ZEB1/2), twist family bHLH 
transcription factor (TWIST), snail family transcriptional 
repressor 1 (SNAIL1/SNAIL) and snail family 
transcriptional repressor 2 (SNAIL2/SLUG) lead to 
changes in the expression of cell surface proteins such as 
cadherins, vimentin and others, subsequently regulating 
cell invasive processes in many tumors, and also in 
gliomas. Silencing of SNAIL1 reduces proliferation, 
invasion and migration of GBM cells [27], and SLUG 
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expression has been found to be higher in GBM specimens 
and correlates to a more invasive phenotype and high grade 
GBM. Moreover SLUG promotes invasion and 
angiogenesis in in vitro and in vivo models [28]. Higher 
ZEB2 expression in human GBM samples correlates with 
fast tumor progression in GBM patients [29]. 
Interestingly, many of these motility pathways and 
mechanisms are interconnected. As example, TGFβ 
promotes glioma cell migration via up-regulation of 
integrin αvβ3 [30] and both STAT3 and TGFβ modulate the 
expression of SLUG, SNAIL and TWIST [31, 32]. 
2.1.3.4 Hypoxia, neoangiogenesis and metabolic 
changes 
During tumor growth, a part of the glioma cells located in 
the inner portion of the tumor can face hypoxia and 
nutrients starvation. Therefore glioma cells developed 
strategies to overcome this adverse situation. First of all, 
around the necrosic and hypoxic regions of GBM 
pseudopalisading cells become prominent. These glioma 
cells change their phenotype to a more migratory 
phenotype in an attempt to leave the hypoxic region and 
reach the closest blood vessel for oxygen and nutrient 
supply [33]. During oxygen deprivation, hypoxia-inducible 
31 
 
factor 1 (HIF1α) is stabilized and induces the expression of 
several genes like vascular endothelial growth factor 
(VEGF), fibroblast growth factor (FGF), stromal cell 
derived factor (SDF) or angiopoietin (ANGPT) that trigger 
neoangiogenic processes [34].  
Glioma cells as well as almost all tumor cells use more 
anaerobic glycolysis to provide energy in place of oxidative 
phosphorylation, the so called Warburg effect. By this, 
tumor cells become more resistant to hypoxia. In addition, 
the expression of glucose transporters and the glucose 
uptake is increased and lactate production is elevated in 
tumor cells. The changes in metabolic activity as well as 
hypoxic conditions induce tumor cell migration and 
invasion, also of glioma cells (for review see [35]). 
2.1.3.5 Immunosuppression 
Glioma cells mainly escape the attack of the immune 
system and for this they use different mechanisms. Glioma 
secreted TGF-β, besides its pro-migratory function, is a 
potent immune-suppressive cytokine. It blocks T-cell 
activation and expansion, inhibits natural killer (NK) cells 
activity and, in an autocrine fashion, leads to the 
camouflage of glioma cells by downregulation of major 
histocompatibility complex (MHC) protein expression or by 
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shading of NK-cell ligands expressed on the cell surface. 
Moreover, GBM cells express programmed death-ligand 1 
(PD-L1), which binds to the T cell exhaustion receptor PD-
1, this way inhibiting the activation of tumor  infiltrating T 
cells (for review see [36]). 
2.1.3.6 Glioma stem cells 
As mentioned above, GBM cells show great heterogeneity 
in mutations as well as in their behavior and can change 
their behavior not only by genetic or epigenetic alterations, 
but also reversibly during environmental alterations in the 
surrounding tumor micro-milieu. In this regard it has been 
shown that a small population of glioma cells in the tumor 
harbor stem cell characteristics, are highly therapy resistant 
and are postulated to be responsive for recurrence of this 
disease (for review see [37]). GBM stem cells (GSC) are 
defined as cells sharing normal neural progenitor features 
including the expression of neural stem cell markers [e.g. 
Musashi RNA binding protein 1 (MSI1), nestin (NES), 
SRY-box 2 (SOX2), POU class 5 homeobox 1 (OCT4)], 
having the capacity for self-renewal and neurospheres 
formation. 
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2.1.4 Treatment options for glioma 
The current standard therapy for GBM is surgical resection 
of the tumor followed by radiochemotherapy, known as the 
STUPP regime [6]. The level of resection is case-specific 
depending on tumor size, shape and location. The bigger 
and more accurate the resection, the greater is the chance of 
prolonged survival.  
Radiation therapy causes severe DNA damages leading to 
apoptosis-induced cell death. Radiation therapy can be 
performed as external beam radiation therapy (EBRT) or 
radiosurgically, for example with gammaknife techniques. 
The standard chemotherapy is Temozolomide (TMZ), an 
alkylating agent that methylates purines in DNA. The 
success of the treatment is highly dependent on the genetic 
background of the tumor cells, in particular the methylation 
state of the O-6-methylguanine-DNA methyltransferase 
(MGMT) promoter. MGMT mediates DNA mismatch 
repair after TMZ-induced damage, therefore the treatment 
is more effective when the MGMT promoter is methylated. 
Indeed, patient survival rates are higher in patients with 
MGMT promoter methylation (21.5 versus 15.3 months) 
[38]. Nevertheless, overall survival is still short and novel 
therapies are needed. 
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One new class of therapeutic agents are monoclonal 
antibodies that recognize cell surface receptors or ligands, 
this way disrupting the receptor-ligand interaction and 
preventing the activation of tumor signaling cascades. 
Examples are Avastin /Bevazizumab, an antibody 
neutralizing the function of VEGF, postulated to inhibit 
neoangiogenesis [39] or Erbistux/Cetuximab, an EGFR-
specific monoclonal antibody [40], that has been used in 
tumor therapy due of the high frequency of EGFR 
mutations or amplification in GBM. Some difficulties have 
been observed in this kind of therapy, such as the lack of 
these antibodies to cross the blood-brain barrier, or 
systemic toxicity. Other attempts in immunotherapy have 
been made using vaccine based drugs that target patient 
specific tumor antigens or commonly overexpressed 
antigens in GBM. Besides this several other strategies are 
under observation that should improve the anti-tumoral 
immune response (for review see [41]). Another 
approachto treat GBM is based on the use of oncolytic 
viruses (OV). OV are genetically manipulated to target and 
to kill cancer cells whilst leaving non-neoplastic cells 
unaffected. This is achieved by manipulating the OV in a 
way that makes virus replication possible only in the 
presence of certain cancer specific or proteins 
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overexpressed in tumor cells such as Y-box binding protein 
1 (YB-1), EGFRvIII, platelet derived growth factor 
receptor (PDGFR) or interleukin 13 receptor (IL-13R). 
This approach could be also useful to target the population 
of GSC that are mainly resistant to most available therapies 
(for review see [42]). 
With the most updated diagnostic tools, involving the 
analyses of genetic and molecular profiles of each single 
GBM, the idea of personalized medicine is becoming more 
and more feasible and promising [43].  
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2.2 “GROW OR GO” HYPOTHESIS 
The “Grow or Go” hypothesis (Figure 2.2.1) is based on 
the assumption that a cell is not able to proliferate and 
migrate at the same time, mostly because the two 
mechanism share the same cell component, the 
cytoskeleton, and both requires great energy consumption. 
This phenomenon was first observed in astrocytoma cells 
in 1996, where it was discovered that proliferation and 
migration were mutually exclusive in time. [44]. The 
“Grow or Go” principle might be also of therapeutic 
importance since it is suggested to be involved in the 
progression from benign neoplasms (uncontrolled 
proliferation) to malignant invasive tumors (high 
migration) [45]. This behavior has been largely studied in 
GBM, and even a mathematical model to explain the 
process have been created [46].  
It has been shown that the switch from migration to 
proliferation and vice versa can be caused by changes in 
the microenvironment. For example hypoxia or nutrient 
depletion prompts a tumor cell to “Go”. Eventually the 
migrated cell will re-settle in a new niche providing 
optimal conditions and then adapts itself to “Grow” again 
[45]. Indeed, under hypoxic conditions glioma cells change 
their phenotype to a more pro-migratory one. This change 
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is mediated by metabolic adaptation, and in particular the 
pentose phosphate pathway (PPP) has been demonstrated 
to be prominently used during proliferation and cell 
division whereas glycolysis is the prominent energy source 
during migration [47]. But also changes in cell volume, 
cytoskeleton dynamics, extracellular matrix composition 
influence the “Grow or Go” behavior of glioma cells [45]. 
Moreover, ionizing irradiation, an essential therapy in 
GBM treatment, promotes the switch to the ”Go” 
phenotype in glioma cells [48] with a clear influence on the 
success of the treatment. Besides the physiological 
inducers, other molecules like miRNAs that are involved in 
decision of a cell to “Go or Grow” have been identified so 
far. In response to metabolic stress, mir-451 modulates the 
liver kinase B1 (LKB1)/ adenosine monophosphate-
activated protein kinase (AMPK) pathway. miR-451 levels 
are high during glucose rich conditions and promote 
proliferation, while miR-451 levels are reduced during 
glucose deprivation, paralleled by increased cell migration, 
at the expenses of proliferation. In GBM patients elevated 
miR-451 expression is associated with a shorter survival 
[49]. Another miRNA, highly expressed in glioma cells, is 
mir-9. It regulates the “Grow or Go” by inhibiting 
proliferation and promoting migration [50]. 
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Carboxypetidase E (CPE), the protein of interest of this 
work, has been described to have a pro-proliferative but 
anti-migratory role in GBM cells, therefore contributing in 
the “Grow or Go” behavior of glioma cells [51]. 
 
Figure 2.2.1 Schematic representation of the "Grow or 
Go" hypothesis. Revisited from [48]. 
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2.3 CARBOXYPEPTIDASE E 
Carboxypeptidase E (CPE) was first discovered in 1982 as 
an enkephalin convertase, belonging to a family of 
enzymes that are responsible for removing basic residues 
from pro-peptides [52, 53]. CPE was found to be 
responsible for cleaving the C-terminal basic residues of 
pro-peptides or neuropeptides in endocrine cells and 
neurons. The importance of CPE in the endocrine system 
became even more visible after in CPE
fat/fat 
mice a mutation 
in the CPE gene was found that induces obesity, diabetes 
and infertility [54].  
2.3.1 CPE gene, protein structure and activity 
CPE belongs to M14-like superfamily of enzymes, a group 
of metallo-carboxypeptidases that cleave polypeptides at a 
single C-terminal amino acid, have a recognition site at C-
terminal and contain a Zn
2+
 binding site [55]. In particular, 
CPE belongs to carboxypeptidase B-like (CPB-like) 
enzymes given the fact that it cleaves at basic residues 
(lysine or arginine). There are about 23 genes encoding for 
Zn
2+
-carboxypeptidases and a comparison between CPE 
and CPA/B enzymes shows a very little conservation 
except for the Zn
2+
-carboxypeptidase domain indicating 
that these proteins diverged early in evolution [56]. 
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Interestingly, the similarity between CPE in different 
species is really high, highlighting the importance of this 
protein in early evolution. For the goal of this thesis, it is 
important to know that rat and human CPE are highly 
similar and present a very similar structure. CPE is 
obviously localized in neuropeptides-rich area of the brain 
and in endocrine tissues, such as stomach, colon, oviduct, 
salivary glands, pancreas and adrenal medulla [57]. 
CPE genes contains nine exons [58] and alternative spliced 
transcripts have been identified [59](Figure 2.3.1).  
 
 
Figure 2.3.1 Representation of CPE gene and splicing 
variants [57] 
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One variant encodes for a truncated version of CPE (ΔN-
CPE) which lacks a 98 amino-acids N-terminal region due 
to the presence of an alternative splicing site on the first 
exon. This version has been found to be common and 
highly present in metastatic tumors, for example in breast 
cancer [59].  
CPE variant 1 is alternatively spliced at exon 6, this results 
into an 18 amino acid deletion leading to an enzymatically 
inactive protein and the absence of a functional signal 
peptide necessary for endoplasmic reticulum (ER) 
translocation. Therefore this variant is more likely to be 
secreted in the extracellular space [57]. 
The full-length version of CPE is a 476 amino acids protein 
(Figure 2.3.2), containing a 25 amino acid signal peptide 
which directs pro-CPE to the ER. pro-CPE is further 
processed in the Golgi-Apparatus where the 17 amino acids 
long signal peptide is removed and a mature form of CPE 
is formed, ready to exerts its function. Moreover, CPE 
presents two putative glycosylation sites at Asn139 and 
Asn390 [60] and presents several domains (Figure 2.3.2): (i) 
the enzymatic active site including the Zn
2+
 binding 
domain, (ii) a prohormone sorting signal binding site, (iii) a 
transmembrane domain and (iv) a cytoplasmic tail. 
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The mature form of CPE can be further processed at the C-
terminus (Arg455-Lys456) to form a soluble form (50 kDa), 
which is smaller than the membrane-associated form (53 
kDa) and is also more active [61]. 
 
Figure 2.3.2 CPE model and structure [57] 
A Schematic representation of CPE. B Molecular structure 
model of CPE. 
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2.3.2 CPE in prohormone sorting/processing and 
vesicles transport 
Most cells present a constitutive secretory pathway to 
maintain cell survival, differentiation or growth. Neurons 
and endocrine cells need a tightly regulated secretory 
pathway (RSP) to modulate hormone and neuropeptide 
secretion in order to maintain the homeostasis of the 
organism. CPE is a very important protein involved in 
different steps of this process, as described in Figure 2.3.3. 
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Figure 2.3.3 Trafficking of CPE in regulated secretory 
pathway [57]. 
A CPE and pro-hormones are packed into vesicles from the 
ER. B The cytoplasmic tail of CPE binds dynactin and the 
microtubules. C The vesicles are addressed to the plasma 
membrane. D CPE acts as a sorting receptor. E Processing 
of prohormones by prohormone convertases (PCs) and 
CPE. F Recycling of CPE by ADP-ribosylation factor 6 
(ARF6) recruitment. 
 
Pro-hormones and pro-peptides are synthesized at the 
rough ER and are transported to the Golgi apparatus in 
order to reach the trans-Golgi Network (TGN) together 
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with the processing enzymes. At the TGN the processing 
enzymes, including CPE, and their substrates are packed 
into vesicles for regulated secretion [62]. It is fundamental 
that the pro-hormones or pro-peptides are sorted together 
with their correct processing enzymes. One mechanism 
proposed is aggregation as a concentration step [63] but 
this is not enough to explain the directionality of the RSP. 
CPE presents a pro-hormone sorting signal binding site 
(Arg255 and Lys260), necessary for recognizing motifs 
common for proopiomelanocortin (POMC), proinsulin 
(INS), pro-brain-derived neurotrophic factor (pro-BDNF) 
and proenkephalin (PENK) [62, 64, 65]. The role of CPE 
as a sorting receptor has been described in different models 
and it is the membrane bound form of CPE that is 
responsible for this function. During vesicle transport to the 
plasma membrane, the granules undergo maturation, 
including acidification. This step is really important since 
the enzymatic activity of CPE reaches an optimum at pH 5-
6 and becomes inactive at pH 7.4 [66]. After cleavage, 
mature hormones and neuropeptides are released into the 
extracellular space by exocytosis and transmembrane CPE 
is recycled back to TGN via recruitment and interaction 
with ARF6, a small cytoplasmic GTPase [67].  
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2.3.3 CPE and neuroprotection 
Besides its role in pro-hormone sorting and processing, 
CPE has been found to be involved in the response to 
different stress stimuli and neuroprotection. Neurons of the 
hippocampus or cortex upregulate CPE after ischemic 
stress, leading to neuronal survival. On the contrary, in 
models lacking CPE these neurons become apoptotic after 
ischemic episodes [68, 69]. 
CPE has been described as a neurotrophic factor. In vitro a 
secreted, non-enzymatic form of CPE protects rat 
hippocampal neurons against oxidative stress caused by 
H2O2. This protection activity is mediated by activation of 
the ERK1/2 and AKT pathways, this leading to the 
upregulation of the anti-apoptotic protein BCL-2 and 
inhibition of caspase-3 [70]. Moreover, also ΔN-CPE has 
been found to be transiently expressed in early 
development and, in this time frame, to protect embryonic 
neurons against glutamate-induced neurotoxicity. ΔN-CPE 
is found in the nucleus and here can mediate the 
overexpression of FGF2, which in turn can be secreted and 
subsequently activates ERK1/2 and AKT, also leading to 
enhanced BCL-2 expression [71]. 
CPE has been linked to protection to apoptosis and cell 
survival not only in the brain, but also in other endocrine 
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tissues. There is a correlation between CPE and palmitate-
induced ER stress in pancreatic β-cells. Increased Ca2+ 
influx during palmitate-induced apoptosis is necessary for 
the degradation of CPE, probably given the fact that Ca
2+ 
high levels strongly affect CPE stability. Interestingly, CPE 
overexpression can partially rescue β-cells from the 
apoptotic process caused by palmitate toxicity [72].  
The role of CPE in survival and apoptosis is still under 
investigation, considering a possible involvement in age 
related neurodegenerative disease such as Alzheimer or 
Parkinson disease.  
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2.3.4 CPE and cancer 
The role of CPE in endocrine and non-endocrine tumors 
has been highly investigated. Concerning non-endocrine 
tumors, it is interesting to notice that CPE is not usually 
expressed in the healthy tissues, while it has been shown to 
be expressed (or even highly expressed) in cancers derived 
from the same tissues. CPE is expressed in liver [73] and 
breast cancer cells [74], but not in their respective normal 
tissues. Moreover, CPE is not expressed in cervical or 
colon tissue, but during cancerogenesis its level is 
increased in cervical and colon cancer cells [75]. Even 
though CPE is expressed in the brain, two independent 
studies have shown that CPE is highly expressed in glioma 
biopsies compared to normal brain tissue [76]. Microarray 
expression analyses of tumor biopsies indicate that 
metastatic tumors present higher levels of CPE mRNA 
compared to healthy tissue or benign tumors [75] drawing 
CPE as a biomarker for metastatic tumors. But since most 
of the studies are performed at mRNA level is not clear 
which variant of CPE, namely the pro-tumorigenic ΔN-
CPE variant, is expressed in those tumors. For several 
tumor entities, ΔN-CPE variant has been found to be 
correlated to a high metastatic phenotype and poorer 
prognosis. Overexpression of ΔN-CPE predicts poor 
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prognosis in colorectal cancer patients [77], CPE-ΔN was 
found highly expressed in human hepatocellular carcinoma 
HCC and breast metastatic tumor cell lines, and silencing 
of ΔN-CPE was able to reduce metastasis in mice. 
Moreover, high ΔN-CPE mRNA copy numbers were found 
in biopsies of pheochromocytomas/paragangliomas 
(PHEOs/PGLs) and correlate with the prediction of 
metastasis and recurrence in these patients [59]. In HCC 
cells ΔN-CPE is able to translocate into the nucleus and 
there interacts with histone deacetylase (HD) 1/2. ΔN-CPE 
upregulates the neural precursor cell expressed 
developmentally downregulated gene 9 (NEDD9) and 
enhances invasion and migration of melanoma cell lines 
[59]. 
The involvement of full-lengh CPE in different cancers is 
still under investigation. The function of this CPE variant 
in tumor cells is diverse and modulates cellular processes 
and cascades involved in tumor progression that can be or 
not be dependent on its enzymatic activity. The function of 
CPE in cancer is therefore controversially discussed.  In 
HCC cells CPE, by activation of ERK1/2, can induce the 
expression of pro-survival factors such as BCL-2. 
Otherwise, CPE reduces migration and invasion of 
fibrosarcoma [78] and glioma cell [51]. In colorectal cancer 
50 
 
cell lines CPE is overexpressed and induces proliferation 
and cell growth through downregulation of p21 and p27 
and upregulation of cyclinD1 [79]. CPE can also interfere 
with further signaling cascades involved in cancer 
progression, such as the β-catenin pathway. It has recently 
shown that CPE inhibits the secretion and activity of 
wingless-type MMTV integration site family (WNT) 3a, 
forming non-soluble aggregates with Wnt3a [80]. 
In GBM, CPE has been described as a “Grow or Go” 
factor. In particular a secreted version of CPE was able to 
reduce migration and induce proliferation of glioma cells, 
independently from its enzymatic activity [51]. 
Controversial results have been recently published 
suggesting that CPE can promote proliferation, tumor 
growth and metastasis, but also reduces tumor cell 
migration and invasion. However, it is not clear whether 
these effects (or which effects) are induced by ΔN-CPE or 
by its full length counterpart [81].  
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2.4 AIM OF THE STUDY 
The present thesis project aims to examine the role of a 
secreted version of CPE (sCPE) in the “Grow or Go” 
phenomena in glioma cells, focusing on its anti-migratory 
effects previously shown in our lab. In this regard, changes 
in the expression of motility-associated genes will be 
analyzed as well as signaling cascades that are modulated 
by CPE will be identified. 
The pro-survival and pro-proliferative role of CPE has been 
investigated in other cancer entities, like HCC or colorectal 
cancer (CRC). The ERK1/2 and AKT pathways have been 
proposed to be mediators of CPE-associated effects in these 
cells, resulting in the regulation, among others, of anti-
apoptotic BCL-2 as well as of the cell cycle regulating 
proteins p21
WAF1
 or p27
KIP-1
. However, the detailed 
mechanisms by which CPE modulates glioma cells motility 
have not been investigated so far. In the present study using 
mRNA microarray chip technology we investigate CPE-
mediated changes in gene expression, especially of 
motility-associated genes as well as the functional impact 
of differentially regulated genes in GBM cells. We further 
aim to identify the signaling cascades by which CPE 
transmits its anti-migratory effects in GBM cells. 
Moreover, putative receptors or binding proteins by which 
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sCPE transmits its anti-migratory properties form the 
extracellular space into glioma cells, focusing on the 
identification of secreted, membrane-bound or intracellular 
CPE-binding partners, should be examined.  
Due to its anti-migratory function in GBM cells, CPE 
might be an interesting candidate gene for a novel GBM 
therapy approach. Overexpression of CPE in cancer cells 
might reduce the invasive growth of the tumor, pushing it 
into a more solid one, by this making it better operable. 
Therefore we additionally analyzed whether CPE might 
enhance the effects of GBM standard therapy approaches in 
vitro, and for the first time we investigate the role of CPE 
in orthotopic GBM mouse models.  
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3. MATERIALS AND 
METHODS 
3.1 MATERIALS 
3.1.1 MACHINES 
Machine Model Producer 
Incubators CO2-Incubator Sanyo; Munich, 
Germany 
Microscopes and 
Cameras 
Eclipse TS100 Nikon; Kingston, 
England 
Neugebauer 
counting chambers 
 Marienfeld; Bad 
Mergentheim, 
Germany 
Shaker   
Sterile-Bench Hera Safe Heraeus; Hanau, 
Germany 
Vortexer MS1 minishaker IKA Works; 
Wilmington USA 
Heating block Grant QBT4 Grant; 
Cambridge, 
England 
ELISA-Reader Thermo Electron 
Multiscan EX 
Thermo Electron 
Corporation; 
Karlsruhe, 
Germany 
Gel documentation 
device 
ChemiDoc
TM
 
Imaging System 
Biorad; Munich, 
Germany 
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Multipette  Eppendorf; 
Hamburg, 
Germany 
Spectrophotometer NanoDrop ND 
1000 
Peqlab; Erlangen, 
Germany 
Power source Power Pac Biorad; Munich, 
Germany 
centrifuge Multifuge 3 S-R Heraeus; Hanau, 
Germany 
Table centrifuge Biofuge Pico Heraeus; Hanau, 
Germany 
Immunoblot 
Apparatus 
Biorad Biorad; Munich, 
Germany 
Stereotactic 
apparatus 
Stoelting Stoelting, Dublin, 
Ireland 
automatic 
injection device 
Leica 
nanoinjector 
stepper motor 
precision 
Leica 
microsysteme, 
Wetzlar, 
Germany 
Irradiator  
137
Cs Gammacell 
GC40 
Best 
Theratronics, 
Ontario, Canada 
Thermal cycler Applied 
Biosystems 7500 
Fast Real-Time 
PCR System
 
Thermo Fisher 
Scientific, 
Darmstadt, 
Germany 
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3.1.2 MATERIALS 
Materials Producer 
Filter tips 0.1 – 10 / 10 – 
100 / 20 – 200 / 100 – 1000 
µl 
Gilson; Middelton, USA 
plastic pasteur pipetts Ratiolab; Dreieich, Germany 
Pasteur pipetts WU; Mainz Germany 
Plastic pipetts 5 / 10 / 25 / 
50 ml 
Corning; New York, USA 
Pipett tips 0.1 – 10 / 10 – 
100 / 20 – 200 / 100 – 1000 
µl 
Ratiolab; Dreieich, Germany 
Glass slides 26 x 76 mm Langenbrinck; 
Emmendingen, Germany 
Falcon 15 / 50 ml Corning; New York, USA 
Reaction tubes with lid 1,5 / 
2 ml 
Greiner Bio-One; 
Frickenhausen, Germany 
Hypodermic needles Braun; Meisungen, Germany 
Cell culture flasks Greiner Bio-One; 
Frickenhausen, Germany 
Cell culture plates Corning; New York, USA 
parafilm Pechiney; Chicago, USA 
PVDF membrane Carl Roth; Karlsruhe, 
Germany 
Cell culture inserts Schubert & Weiss 
OMNILAB, Munich, 
Germany 
Hamilton syringe10μl MedChrom, Dalsheim, 
Germany 
Perma-hand seide (suture 
material) 
Ethicon, Livingstone, 
Scotlaand 
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Sterile surgical blades Braun Aesculap, Tuttlingen, 
Germany 
Optical adhesive film Thermo Fisher Scientific, 
Darmstadt, Germany 
ABGene PCR plates Thermo Fisher Scientific, 
Darmstadt, Germany 
 
3.1.3 CHEMICALS 
Chemical Producer 
Ammonium persulfate 
(APS)  
Carl Roth; Karlsruhe, 
Germany 
Bovines Serum Albumin 
(BSA) 
Carl Roth; Karlsruhe, 
Germany 
Calcium chloride (CaCl2)  Sigma-Aldrich; Steinheim, 
Germany  
Dimethyl sulfoxide 
(DMSO)  
Carl Roth; Karlsruhe, 
Germany 
Dithiothreitol (DTT)  Carl Roth; Karlsruhe, 
Germany 
Ethanol 99% Merck; Darmstadt, Germany 
Glycerol Carl Roth; Karlsruhe, 
Germany 
Glycin  Carl Roth; Karlsruhe, 
Germany 
Skim milk powder Carl Roth; Karlsruhe, 
Germany 
Methanol  VWR; Darmstadt, Germany 
Hydrochloric acid (HCl) 
(37%)  
Carl Roth; Karlsruhe, 
Germany 
Sodium dodecyl sulphate Carl Roth; Karlsruhe, 
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(SDS)  Germany 
Tetramethylethylediamine 
(TEMED)  
Carl Roth; Karlsruhe, 
Germany 
Tris Base  Sigma-Aldrich; Steinheim, 
Germany  
Triton X-100  Sigma-Aldrich; Steinheim, 
Germany  
Acrylamide Carl Roth; Karlsruhe, 
Germany 
Bradford Reagent Carl Roth; Karlsruhe, 
Germany 
Bromophenol blue Merck; Darmstadt, Germany 
Isopropanol Merck; Darmstadt, Germany 
Igepal (NP-40) Sigma-Aldrich; Steinheim, 
Germany  
Sodium chloride Merck; Darmstadt, Germany 
Tween-20 Carl Roth; Karlsruhe, 
Germany 
Potassium chloride Carl Roth; Karlsruhe, 
Germany 
Magnesium chloride Carl Roth; Karlsruhe, 
Germany 
Hydroxyethylpiperazine 
ethane sulfonic acid 
(HEPES) 
Carl Roth; Karlsruhe, 
Germany 
Ethylenediaminetetraacetic 
acid (EDTA) 
Sigma-Aldrich; Steinheim, 
Germany  
Sodium azide (NaN3) Carl Roth; Karlsruhe, 
Germany 
Acetic acid Carl Roth; Karlsruhe, 
Germany 
Diethyl pyrocarbonate 
(DEPC) 
Sigma-Aldrich; Steinheim, 
Germany 
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3.1.4 OTHER SUBSTANCES 
Substance Producer 
Full Range Rainbow 
Molecular Weight Marker  
PanReac AppliChem; 
Darmstadt, Germany 
Proteinase K (20mg/mL)  G Bioscience; St. Louis, 
USA 
Phospho-Stop Roche; Mannheim, Germany 
WesternBright ECL HRP 
Substrate 
Advansta; California, USA 
Mayer’s Hematoxylin 
solution 
Merck, Darmstadt, Germany 
Moviol  Carl Roth; Karlsruhe, 
Germany 
Decosept AF Dr Schuhmacher; Malsfeld-
Beiseförth, Germany 
Carpofen, Antidots, 
Narcotics 
Veterinary Support Unit, 
University of Tuebingen 
Bepanthen Bayer Vital, Leverkusen, 
Germany 
PeqGOLD TriFAST 
(Trizol) 
PeqLAB, Germany 
Oligo-d(T20) Sigma-Aldrich; Steinheim, 
Germany 
M-MLV Reverse 
Transcriptase 
Promega, Mannheim, 
Germany 
Viromer BLUE Biozym, Hessisch Oldendorf, 
Germany 
dNTP mix PeqLAB, Germany 
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3.1.5 KITS 
Kit Producer 
NucleoSpin RNA plus Machery-Nagel, Dueren, 
Germany 
MycoAlert Mycoplasma 
Detection Kit 
Lonza; Köln, Germany  
SensiMix SYBR low-Rox 
KIT 
Bioline, Berlin, Germany 
Pierce BCA Protein assay 
kit 
Thermo Fisher Scientific, 
Darmstadt, Germany 
 
3.1.6 CELL CULTURE 
Medium / Supplement Producer 
Puromycin Applichem, Darmstadt, 
Germany 
Dulbecco’s modified eagle 
medium (DMEM) 
Sigma-Aldrich; Steinheim, 
Germany  
Fetal Bovine Serum (FBS)  Sigma-Aldrich; Steinheim, 
Germany  
G418 sulfate Biochrom, Berlin, 
Germany 
PBS-DULBECCO Sigma-Aldrich; Steinheim, 
Germany  
Recombinant human 
„Epidermal Growth 
Factor“ (EGF)  
Biomol; Hamburg, 
Germany  
Trypsin  Sigma-Aldrich; Steinheim, 
Germany  
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Acutase Sigma-Aldrich; Steinheim, 
Germany  
Mitomycin C Sigma-Aldrich; Steinheim, 
Germany  
Penicillin/Streptomycin PAA Laboratories; Cölbe, 
Germany 
U-0126 MEK inhibitor Selleckchem, Munich, 
Germany 
S3I-201 STAT3 inhibitor Sigma-Aldrich; Steinheim, 
Germany 
Temozolomide (TMZ) Sigma-Aldrich; Steinheim, 
Germany 
Lentivirus LPP-NEG-
Lv105-025-C 
GeneCopoeia, Rockville, 
Maryland 
Lentivirus LPP-FO192-
Lv-105-050-S 
(expressing human CPE) 
GeneCopoeia, Rockville, 
Maryland 
MISSON esiRNA human 
SNAI2 
Sigma-Aldrich; Steinheim, 
Germany 
MISSION esiRNA Egfp Sigma-Aldrich; Steinheim, 
Germany 
Ad-CMV-EGFP Vector Biolabs, USA 
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3.1.7 SOFTWARES 
Software Producer 
Word Office Microsoft 
Power Point Office Microsoft 
Excel Office Microsoft 
ImageJ Fiji 
Image Lab Version 5.1 Biorad 
Ascent Software 2.6 Thermo Fisher 
Scientific 
Inveon Research Workplace 3.1 Siemens Preclinical 
Solutions 
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3.2 METHODS 
3.2.1 Cell lines and cell culture 
LNT-229 and LN-308 cells were kindly provided by N. de 
Tribolet (Lausanne, Switzerland) and T98G cells were 
provided by American Type Culture Collection (ATCC, 
Wesel, Germany). These cell lines were characterized for 
main mutations involved in cancer progression by Ishii et 
al. and their genotype is reported in Table 3.2.1. GBM 
primary cells Tu-132 and Tu-140 were generated from 
human grade II glioma (71 year old male patient) and 
human grade IV GBM (41 years old female) specimens 
respectively and used at passage 3-10. All cells were 
maintained in DMEM, containing 10% FBS, penicillin 
(100 U/ml)/streptomycin (100 μg/ml) and the appropriate 
selection antibiotics in a humidified atmosphere containing 
5% CO2 at 37°C. Cells were splitted at approximately 80% 
confluency. The cells were routinely treated with BioMyc1 
and BioMyc2 and tested for mycoplasma contamination 
prior to the experiments. Only mycoplasma-negative cells 
were used for experiments. 
Rat CPE-overexpressing cells were generated by 
transfection with pcDNA3-CPE (LNT-229-rCPE) or the 
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empty control vector pcDNA3 (LNT-229-neo) as 
previousely described [51]. At least 2 different cell clones 
were used in the analyses.  
Table 3.2.1Cell lines characterization [82] 
CELL 
LINE 
p53  PTEN p16INK4A p14ARF 
LNT-229 
(i) Heterozygotic 
wildtype – mutant  
CCT(Pro)→CTT(Lys) 
(ii) 100% 
transcriptional activity 
based on reporter 
genes analyses 
wildtype deleted deleted 
LN-308 deleted 
splice 
(deletion 
exon 6) 
wildtype wildtype 
T98G 
mutated 
ATG(Met)→ATA(Ile) 
 
mutated 
CTT(Leu)→
CGT(Arg) 
deleted deleted 
3.2.2 Generation of human CPE-overexpressing cells 
Stable human CPE-overexpressing glioma cells were 
generated by lentiviral transduction. The cells were seeded 
in 24-well plates (4x10
4cells/well/500μl) in complete 
growth medium and allowed to attach overnight. For each 
well, 500 μl of virus suspension was prepared in complete 
growth medium containing 5μg/ml polybrene and 10 MOI 
(Multiplicity of infection) of pReceiver-LV105 lentivirus 
expressing human CPE and control of the CMV promoter 
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and the selection marker gene for puromycin resistance, or 
its empty counterpart. Culture medium was removed and 
replaced with 500 μl of viral supernatant. Plates were 
placed for 2 hours at 4°C and were afterwards transferred 
to 37°C. The next day the virus containing medium was 
replaced by fresh growth medium. 72 hours after 
transduction the cells were transferred to 6-well plates and 
selection was started by adding puromycin (2 μg/ml). CPE 
overexpression and secretion was analyzed by immunoblot 
every 5
th
 passage.  
3.2.3 Experimental treatment 
For the experiments, cells were seeded in complete growth 
medium in 6-, 12-, 24- or 96- well plates depending on the 
experiment and allowed to attach. After 24 hours, culture 
medium was substituted by growth medium or serum free 
medium (SFM) supplemented with the agents indicated for 
each experiment. U0126, a specific MEK inhibitor, was 
used at the concentration of 10 μM and S3I-20, a STAT3 
inhibitor, at the concentration of 30 μM. Temozolomide 
(TMZ) was used at different concentration ranging from 
0.3 to 3 μM. For irradiation, cells were irradiated with 2 or 
4 Gy in a 
137Cs Gammacell GC40.EGF (10μM) treated 
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cells were used to generate positive controls for either 
phosphor-ERK1/2 or phospho-STAT3.  
 
3.2.4 Transcriptome and miRNAome profiling 
experiments 
Sample preparation 
LNT-229-neo and –rCPE cells were used in these analyses 
in triplicates. Cell pellets from 1.5x10
7
 cells were generated 
and were resolved in 1.5 ml of Trizol, homogenized by 
inversion and incubated at room temperature for 5 minutes. 
After centrifugation, 300 μl of chloroform were added to 
the pellet and vortexed for 15 seconds. Samples were left 
10min at room temperature and then centrifuged at 12,000 
rpm for 15 minutes at 4°C. The aqueous phase was 
transferred into a new tube. 750ul of isopropanol were 
added for precipitation. After incubation for 10 minutes at 
room temperature, samples were centrifuged at 12,000 rpm 
for 30 minutes at 4°C. Pellets were rinsed twice with EtOH 
75%, dried, resuspended in 200 μl of DEPC-treated RNase-
free water and stored at -80°C. Samples were sent in dry 
ice for further analysis to the Genomics and Proteomics 
Research Unit, Department of Oncology, Luxembourg 
Institute of Health (L.I.H.) Luxembourg. 
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Analysis  
Analysis was performed and method description was 
provided by T. Kaoma (Genomics and Proteomics 
Research Unit, Department of Oncology, Luxembourg 
Institute of Health (L.I.H.) Luxembourg). RNA purity and 
integrity were monitored using NanoDrop® ND-1000 
spectrophotometer and Agilent 2100 Bioanalyzer with 
RNA 6000 Nano assay kit. Only RNAs with no sign of 
contamination or marked degradation (RNA integrity 
number (RIN) > 9) were considered good quality and used 
for further analysis. Transcriptome and miRNAome 
profiles were determined in triplicate RNA samples using 
the Affymetrix Human Transcriptome Array (HTA) 2.0 
and miRNA 4.0 Genechip arrays, respectively. For whole-
transcript expression analysis, 100 ng of total RNA was 
processed and labeled using the GeneChip WT PLUS 
Reagent kit (Affymetrix), whereas for miRNA analysis, 
500 ng of total RNA was processed using the FlashTag 
Biotin HSR RNA labelling kit (Genisphere, USA) 
according to the manufacturer’s standard protocols (P/N 
4425209 Rev.B 05/2009, P/N 702808 Rev.6, and P/N 
703095 Rev3). Upon hybridization of labeled products, 
arrays were washed and stained using the Affymetrix 
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GeneChip WT Terminal Labeling and Hybridization kit, 
before being scanned using a GeneChip Scanner 3000. 
3.2.5 Microarray data analysis 
Analysis was performed in collaboration with A. Mueller 
(NORLUX Neuro-Oncology Laboratory, Luxembourg 
Institute of Health, Luxembourg) who also provided the 
methods description. CEL files generated upon array 
scanning were imported into Partek® Genomics Suite TM 
(GS) 6.6 for preprocessing. Partek was set up to run 
standard Robust Multi-array Average (RMA) at the 
probeset level. Resulting log2 probeset intensities were 
then imported into R statistical environment 
(http://www.R-project.org/) for further analysis. First, log2 
intensity values were summarized to estimate the 
expression level of each transcript cluster (TC) by 
averaging the intensity signals from the corresponding 
probeset regions. Matching between probesets, TCs and 
targeted genes was verified through Affymetrix annotation 
files (HTA-2_0 probeset and transcript hg19 na33.1 csv 
file). The quality of the data was then evaluated by 
assessing repeatability Pearson’s correlation coefficients, 
and through visual inspection of density plots and relative-
log expression plots. Principal component analysis was also 
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used to reduce dimensionality of the data, visualize the 
concordance between biological replicates, and assess if the 
variability in data actually reflected what was expected 
from the experimental design. Finally, the LIMMA 
package (R/Bioconductor) was used to estimate the 
statistical significance of TC expression level differences 
between LNT-229-rCPE and LNT-229-neo samples as the 
reference. Resulting p-values were adjusted for multiple 
testing error using the Benjamini and Hochberg’ false 
discovery rate (FDR) [83]. Elements with a FDR less than 
0.05 were considered as differentially expressed (DE), 
irrespective of the fold-change.  
MiR chip data were analyzed similarly as HTA data with 
some adjustments. First, intensity signals from probesets 
targeting non-human transcripts were filtered out from the 
analysis. Second, no summarization of intensity signals 
was performed as the design of miRNA 4.0 did not include 
any TC level. Microarray expression data are available at 
ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) under 
the accession numbers E-MTAB-5297 and 5299. 
Transcript clusters with FDR < 0.05 were considered as 
significantly differentially expressed. The QIAGEN’s 
Ingenuity® Pathway Analysis software (IPA®, QIAGEN 
Redwood City, www.qiagen.com/ingenuity) was used for 
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transcript cluster mapping and data mining including 
functional analyses, upstream analysis and gene network 
reconstruction. Right-tailed Fisher’s exact test was used to 
calculate a p-value for functional enrichment analysis 
(threshold: -log(p-value) > 1.301). Identification of 
differentially regulated miRNAs associated with the 
regulation of cell motility was reached by a combined 
analysis of IPA and open access softwares: mirtargetlink 
(https://ccb-web.cs.uni-saarland.de/mirtargetlink), RefGene 
(www.refgene.com), mirtarbase (www.mirtarbase. 
mbc.nctu.edu). IPA analyses was based on significant 
mRNA (FDR<0.01) and miRNA (FDR<0.05) and on the 
following criteria: (i) there is a known miRNA - mRNA 
target interaction described and (ii) the expression pairing 
must be opposite (either mRNA downregulated and 
miRNA upregulated or vice versa). 
3.2.6 RNA preparation and quantitative RT-PCR 
For RNA preparation 5x10
5
 cells were seeded in growth 
medium in 6-well plates, were allowed to attach overnight 
and subsequent medium change. At defined time points 
(mainly 24h or otherwise as specified) the cells were 
washed once, scraped and re-suspended in cold PBS. Cells 
were harvested by centrifugation (1200 rpm, 5 min.). Total 
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RNA was isolated from cell pellets using NucleoSpin RNA 
plus columns. RNA purity and concentration was measured 
using Nanodrop. 5 μg of RNA, mixed with oligo-dT20 
(10ng/μl) and dNTPs (0,5 mM), was reverse-transcripted 
using M-MLV Reverse Transcriptase (200 U) in a total volume 
of 20 μl. 5 μl of 1:10 diluted cDNA of each sample was 
used in a total volume of 15 μl of 2x PCR mix (SensiMix 
SYBR low-Rox KIT), along with gene specific forward and 
reverse primers (250 nM) as listed in Table 3.2.2. PCR 
protocol includes 40 cycles of: 95 °C (30 s), 56 °C (30 s) 
and 72 °C (30 s). A reference sample (RS) was included in 
every RT-PCR to allow comparison of different RT-PCR 
runs. Relative mRNA expression of each gene of interest 
(GOI) was quantified by using PRPL0 or GAPDH as 
housekeeping control genes. 
∆CT=CT(GOI)-CT(housekeeping) 
∆∆CT=∆CT(sample)-∆CT(RS) 
n-fold expression= 2
∆∆CT(GOI) 
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Table 3.2.2 Primers list 
 
GENE FORWARD REVERSE 
MGST1 
GGTTTTGTTTATGGTAC
TTCAGAGT 
TGTGAATTGTTCATTTA
GATGTGCC 
PCDH17 
AGTTTGTTCAAAGTAGC
TCCACG 
TCACAGCAGGAGCCTTT
GTT 
PTPRD 
ATGTCAGAGAGCTGCG
AGAA 
TAAGGCATTGGTGACCC
CAC 
MGAT4A 
TGGTGTTGCAGAAGGA
ATGGT 
TCAGATGATCAGTTGGT
GGCT 
SNAI2 
CATACCACAACCAGAG
ATCC 
GAGGAGTATCCGGAAA
GAGG 
ADAMST
4 
GACAAGTGCATGGTGT
GCG 
GCCGGACAAGAATGTG
GGT 
CD9 
AAACGCTGAAAGCCAT
CCAC 
GATGGCATCAGGACAG
GACTT 
CDCA7L 
TTTAACGCCCCCAGTGA
TGA 
GACTCCACGACCTGTTT
CCC 
SPP1 
GCCGAGGTGATAGTGT
GGTT 
ACGGCTGTCCCAATCAG
AAG 
CDKN1A 
(P21) 
GATGACAAGCAGAGAG
CCCC 
ACTCCCCACATAGCCCG
TAT 
STC1 
AAGATGGCGACCACCA
AAGT 
GCAGTGACGCTCATAA
GGGA 
PRPL0 
GAGTCCTGGCCTTGTCT
GTGG 
TCCGACTCTTCCTTGGC
TTCA 
GAPDH 
TCAACGGATTTGGTCGT
ATTGG 
CTTCCCGTTCTCAGCCT
TGAC 
rCPE 
ATGGCCGGGCGCGGAG
GAC 
CAGCTCGATGACCAGG
AGCTC 
huCPE 
ATGGGAATGAGGCTGT
TGGAC 
GGCATGATGTGAATGC
GGGTA 
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3.2.7 Western blot 
For cell lysates 5x10
5
 cells were treated as indicated, 
washed once with ice-cold PBS, scraped, re-suspended in 
cold PBS and centrifuged (5 min, 1200 rpm). Cell pellets 
were lysed in lysis buffer (Table 3.2.3) for 15 minutes on 
ice, centrifuged 15 minutes at 13.000g to remove the not 
soluble fraction, and clarified cell extracts were transferred 
to new vials. Protein determination was performed using 
the Bradford assay [84]. Cell pellets collected for EGFR 
detection were lysed in RIPA buffer (Table 3.2.3) and 
protein concentration was determined using the BCA assay 
[85].  
For the preparation of secreted proteins, 5x10
5
 cells were 
treated under serum free conditions and supernatants were 
collected 48 h later. Cell debris were removed by 
centrifugation and protein concentration was analyzed as 
described before. 30 μg of secreted protein (otherwise 
specified) were precipitated using 3 volumes of ice-cold 
acetone and dried. Proteins were re-suspended in Laemmli 
buffer (Table 3.2.3), heated at 95 °C for 10 min and loaded 
on 8% or 10% gels for SDS-PAGE (Table 3.2.3). 
Electrophoresis was performed at 200 mV in running 
buffer (Table 3.2.3). Transfer on PVFD membranes using 
transfer buffer (Table 3.2.3) was performed at 100 mV for 
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1 hour or 25mV overnight for EGFR detection. Membranes 
were blocked in blocking buffer (Table 3.2.3) for 1 h, 
exposed overnight to the primary antibody (Table 3.2.4) in 
TS-TMBSA (Table 3.2.3) at 4 °C. After washing, blots 
were exposed for 1 h to HRP-conjugated anti-mouse or 
anti-rabbit secondary antibody (1:10.000, Table 3.2.4) 
Immunoreactivity was visualized with Chemiluminescent 
HRP Substrate and detected with ChemiDocTM Imaging 
System. GAPDH or Tubulin was used as loading controls. 
Poinceau S staining was performed to prove correct loading 
of secreted proteins.  
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Table 3.2.3 Western blot buffers 
solution  
Lysis buffer 
50 mM Tris-HCl, pH=8, 120 mM NaCl, 
5mM EDTA, 0.5% NP-40, phosphatase 
inhibitor, protease inhibitor 
RIPA buffer 
50 mM Tris-HCl, pH=8, 150 mM NaCl, 1% 
NP-40, deoxycholate 0.5 %, SDS 0.1 %,  
phosphatase inhibitor, protease inhibitor 
Laemmli buffer 
100 mM Tris HCl pH 6.8, 4% SDS, 0.2% 
bromphenol blue,  
20 % glycerol, 10% 2-mercaptoethanol 
Resolving gel 
30% acrylamide mix, 1.5 M Tris-HCl, 
pH=8.8, 8-10% SDS, 10% APS, TEMED, dd 
H2O 
Stacking gel 
30% acrylamide mix , 0.5 M Tris-HCl, 
pH=6.8, 10% SDS, 10% APS, TEMED, dd 
H2O 
Running buffer 5 mM Tris HCl, 38.6 mM Glycine 
Transfer buffer 
2.5 mM Tris HCl, 19.2 mM Glycine, 20 % 
methanol 
TBS 
50 mM Tris HCl, 150 mM NaCl, 0.05% v/v 
Tween-20 
TS-TMBSA 
10 mM Tris HCl, 150 mM NaCl, 0.1 % 
Tween 20, 5 % skim milk powder, 2 % BSA, 
0.001 % sodium azide, pH was set to 7.4 
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Table 3.2.4 Antibody list 
antibody 
Ref. 
number 
Provider 
Slug (C19G7) Rabbit mAb #9585 Cell signaling 
p21 Waf1/Cip1 (12D1) 
Rabbit mAb  
#2947 Cell signaling 
Anti-α tubulin (rabbit) sc-12462-R 
Santa Cruz 
Biotechnology 
Mouse polyclonal anti-
human TIMP-2 
Mab971 
R&D Systems; 
Minneapolis, USA 
Rabbit monoclonal anti-
human MMP-14 
2010-1 
Epitomics; 
Burlingame CA, 
USA 
Rabbit anti-human MMP-2 #4022 Cell signaling 
Anti-GAPDH (rabbit) sc-25778 
Santa Cruz 
Biotechnology 
Purified mouse anti-
Carboxypeptidase E 
NBP2-
15699 
Novus 
Anti-Bcl2 (mouse) sc-509 
Santa Cruz 
Biotechnology 
Stat3 (124H6) Mouse mAb  #9139 Cells signaling 
Phospho-Stat3 (Ser727) 
Antibody (rabbit) 
#9134 Cell signaling 
Anti-ERK1/2 (mouse) sc-135900 
Santa Cruz 
Biotechnology 
PathScan® Multiplex 
Western Cocktail I: 
Phospho-p90RSK, Phospho-
Akt, Phospho-p44/42 
MAPK (Erk1/2) and 
Phospho-S6 Ribosomal 
Protein Detection Cocktail I  
#5301 Cell signaling 
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Phospho- EGFR Receptor 
Antibody Sampler Kit 
#9922 Cell signaling 
Goat anti-mouse IgG-HRP sc-2005 
Santa Cruz 
Biotechnology 
Goat anti-rabbit IgG-HRP sc-2004 
Santa Cruz 
Biotechnology 
3.2.8 Proliferation assay 
Cells were seeded in growth medium in 96-well plates 
(1x10
4
 or 5x10
4
) and allowed to attach overnight before 
treatment. Cell growth was analyzed using crystal violet 
staining as described [86]. Stained cells were solved in 
natrium citrate and absorbance was measured at 570 nm as 
indication of cell density.  
3.2.9 Migration measurements 
Migration was measured using either wound healing 
(scratch) assay or transwell migration chambers. For the 
wound healing scratch assay 3x10
5 
cells were seeded in 
growth medium in 12-well plate and allowed to attach. The 
scratch was performed using a 100 or 1000 μl pipette tip 
and debris was removed by washing the cells. Migration 
was monitored photographically at defined time points.  
In transwell migration assays 2x10
4 
cells were seeded in the 
upper layer of 8 µm pore-sized Boyden transwell 
chambers. Cells were allowed to actively migrate for 18 
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hours towards FCS containing DMEM as attractant 
medium placed in the bottom chamber. Cell from the upper 
part of the membrane were removed using Q-tips. Migrated 
cells on the lower layer of the membrane were fixed in cold 
methanol for 10 min., stained with Mayer’s Hematoxylin 
solution for 20 minutes and washed in water. The 
membranes were transferred to glass slides and covered 
using Moviol. Stained cells were counted and seven areas 
for each membrane were taken for analysis. Number of 
migrated cells was normalized to the total number of cell, 
assessed in parallel as cell density by cristal violet staining. 
3.2.10 Clonogenic survival assay 
250 cells were seeded in growth medium in 6-well plates, 
allowed to attach and irradiated (0, 2 or 4 Gy). 
Alternatively, the cells were treated with TMZ (0, 3 ,1 or 3 
μM) for 24 h. After treatment, the medium was replaced 
and after 2 weeks cell colonies were stained using crystal 
violet. Visible colonies (> 50 cells) were counted and the 
survival fraction was calculated according to the following 
formula:  
plating efficiency(PE) = number of colonies 
counted/number of cells plated *100 
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survival fraction(SF) = PE of treated sample/PE of control 
*100 
The Webb method was used to calculate synergism [87]. 
3.2.11 Infection of cells with recombinant adenovirus 
3,5 x 10
5 
cells were seeded in growth medium, allowed to 
attach and were infected with  Ad-CMV-SNAI2 or Ad-
CMV-EGFP as negative control. The construction of Ad-
EGFP has been described [88]. For the generation of Ad-
SLUG, human SNAI2/SLUG cDNA was cloned into 
pTRACK-CMV using the Ad-Easy system provided by B. 
Vogelstein (Baltimore, MD, USA) [89]. 
3.2.12 Transfection of cells with si-RNA 
8 x 10
4 
cells were seeded in 24-well plates in and allowed 
to attach. Transfection was performed using  the 
ViromerBlue transfection kit. siRNA constructs (siSNAI2 
or siEGFP as negative control) were diluted in Buffer Blue 
at the concentraction of 2.8 μM, mixed with a 1:9 solution 
of Viromer Blue and Buffer Blue and let 15 min RT. 50 μl 
were added in complete growth medium in each well at the 
final concentration of 25 mM. After 24 hours, cells were 
lysed for RNA collection or seeded for cell transwell 
migration. Detailed protocols can be found at 
https://viromer-transfection.com. 
79 
 
3.2.13 Animal experiment 
4-weeks-old female mice athymic FoxN1-deficient NMRI 
nude mice were purchased from Janvier (St. Berthevin, 
France). Mice were kept in filter-top cages at 22 °C, 60% 
humidity. Sterilized food and water were accessible ad 
libidum. Animals were anesthetized by intraperitoneal 
injection (0,1 ml/10g) of a mixture of 3-components-
narcotic (0,5 mg/kg Medetomidin, 5 mg/kg Midazolam and 
0,05 mg/kg Fentanyl). LNT-229-neo or -rCPE cells (2 
independent experiments), LNT-229-ctrl or –hu-CPE cells 
or LN-308-ctrl or -huCPE were used in the animal 
experiments. 10
5
 cells were injected intracranially in 2 μl 
PBS in the right striatum. Anesthesia was abrogated by 
subcutaneous injection (0,1 ml/10g) of antidot mixture (1,2 
mg/kg Naloxon, 0,5 mg/kg Flumazenil and 2.5 mg/kg 
Atipamezol). For analgesis, 0,1 ml/10g of Carprofen was 
injected subcutaneously. Mice were weighted and checked 
three times a week and were sacrified at appearance of 
neurological symptoms. Survival was evaluated by 
performing Kaplan-Meier survival analyses. 
3.2.14 MRI imaging 
MRI imaging of mice was performed in collaboration with 
M. Krüger (Werner Siemens Imaging Center, Department 
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of Preclinical Imaging and Radiopharmacy, Eberhard Karls 
University, Tuebingen, Germany). On different days post 
implantation of tumor cells, animals were anesthetized with 
a mixture of 1.5% isoflurane (Abbott, Wiesbaden, 
Germany) evaporated in oxygen at a flow of 0.5 l/min. 
Subsequently, animals were placed in a 1 T Icon-Scanner 
(Bruker, Ettlingen, Germany) equipped with a mouse brain 
coil and T2-weighted images of the brain were acquired. 
Body temperature was maintained at 37 °C by a heating 
system and a rectal temperature sensor. Tumor volumes 
were determined by manually drawing regions of interest in 
the MR images in Inveon Research Workplace 3.1 
(Siemens Preclinical Solutions, Erlangen, Germany) and 
creating volumes of interest 
3.2.15 Statistic analysis 
The figures show data obtained in at least three 
independent experiments as indicated. Statistical analyses 
were performed using Excel, Microsoft. Quantitative data 
was assessed for significance by t test (*p < 0.05; **p < 
0.01; ***p < 0.005). Statistical analysis for clonogenic 
survival assay was performed used the Webb Method [87]. 
Survival of mice was analyzed by Kaplan-Meier life tables. 
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Wilcoxon and log-rank test were used for comparison of 
survival (significance level α = 0.05).   
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4. RESULTS 
4.1 Effects of CPE on proliferation and 
migration of GBM cells 
In a recent publication of our lab it has been shown that 
overexpression of rat CPE on the one hand mitigates 
migration of glioma cells and on the other hand induces 
proliferation [51], indicating that CPE might be a switch 
factor regulating the “Grow or Go” behavior of glioma 
cells.  
For this we generated, besides rat CPE-overexpressing 
LNT-229 cells that are available in the lab, human CPE-
overexpressing glioma cell lines using lentiviral 
transdution. Expression of sCPE was demonstrated in cell 
supernatants generated from LNT-229-rCPE and 
lentivirally huCPE transduced LNT-229, T98G, LN-308 
and Tu-132 glioma cells and their control transduced 
counterparts (Figure 4.1.1). 
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Figure 4.1.1 Analysis of sCPE secretion in CPE-
overexpressing GBM cells. Immunoblot detection of 
sCPE in supernatants derived from CPE-overexpressing 
LNT-229 (either rat or human CPE), T98G, LN-308 and 
Tu-132 cells. Ponceau staining was used to demonstrate 
equal protein loading (n = 3, one representative experiment 
is shown). 
  
LNT-229   LNT-229 T98G       LN-308     Tu-132  
sCPE
Ponc.
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In colorectal cancer (CRC) it has been shown that CPE 
modulates proliferation through modulation of cell cycle 
regulator p21 [79]. Therefore we analyzed p21 expression 
in CPE-overexpressing GBM cells (Figure 4.1.2) and found 
lower levels of p21 in all CPE-overexpressing cells.  
 
Figure 4.1.2 CPE modulates p21 expression in GBM 
cells. Immunoblot detection of p21 in CPE-overexpressing 
LNT-229 (either rat or human CPE), T98G, LN-308 and 
Tu-132 cells. Tubulin was used as a loading control. (n = 3, 
one representative experiment is shown) 
 
Nevertheless, significant differences in cell density 
overtime, indicating enhanced proliferation, were observed 
only in rCPE-overexpressing LNT-229 clonal cell lines as 
already shown by Höring et al [51]. No significant 
differences were observed in human CPE-overexpressing 
cells, except for a few time points: day 4 for T98G cell line 
and day 6 for LNT-229 (Figure 4.1.3).  
 
LNT-229   LNT-229 T98G       LN-308     Tu-132  
p21
Tubulin
BCL-2
Tubulin
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Figure 4.1.3 Effects of CPE overexpression on the 
proliferation of GBM cells. Cell growth was analyzed in 
CPE-overexpressing LNT-229 (either rat or human), T98G, 
LN-308 and Tu-132 or their sibling control cells. Crystal 
violet staining performed every 24 hours for LNT-229 
(n=6) and T98G (n=3), every 48 hours for LN-308 (n=6) 
and Tu-132 (n=3, SEM, * p < 0.05, ** p < 0.01).  
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Using transwell migration chambers (Figure 4.1.4) we 
showed that overexpression of CPE led to a significant 
reduction in the number of migrated cells in all GBM cell 
lines and primary GBM cells tested so far. The same effect 
of CPE was previously described by Höring et al for rCPE-
overexpressing clonal LNT-229 and LN-308 glioma cell 
lines [51]. Consistently and as demonstrated before for 
LNT-229 cells [51], siRNA-mediated downregulation of 
CPE in highly CPE-expressing Tu-140 glioma primary 
cells induces cell motility (experiment performed by our 
collaborator E. Ilina, Goethe University, Frankfurt). These 
data prompted us to focus on the effects of CPE on glioma 
cell motility, considering that CPE effects on cell growth 
may be species-specific, whilst a general effect of both rat 
and human CPE on migration has been demonstrated.  
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Figure 4.1.4 Effects of CPE on the migration of GBM 
cells. Cell migration was analyzed by using transwell 
migration chambers. Right panel: migration of LNT-229, 
T98G, LN-308 and Tu-132 control (black bars), rat CPE- 
(gray bars) or human CPE- (white bars) overexpressing 
cells (n=3, SEM); left panel: migration of Tu-140 cells 48 h 
after transfection with either siCPE or non-target siRNA 
(si-NT; n=3, SEM). The latter experiment was performed 
by E. Ilina, Goethe University, Frankfurt. * p < 0,05, 
**p<0,01. 
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4.2 Transcriptome analyses: CPE modulates 
mRNA as well miRNA expression associated 
to signal transduction cascades and genes 
involved in the regulation of cell motility 
As demonstrated in chapter 4.1, sCPE significantly 
mitigates glioma cell migration. Since sCPE is, at least 
partially, responsible of this effect, the extracellular signal 
provided by sCPE has to be transmitted to the intracellular 
compartment to provide the anti-migratory function of 
sCPE. We hypothesize that the sCPE-mediated reduction of 
glioma cell migration will be associated with changes in 
the expression of motiliy-associated genes. We therefore 
performed mRNA and miRNA expression micro-array 
analyses of faster migrating LNT-229-neo and slower 
migrating LNT-229-rCPE cells. Using mRNA expression 
microarray and IPA, we found with a false discovery rate 
(FDR) of < 0.01 that 1065 mRNA were differentially 
expressed. In this cohort, at least 100 genes were either 
directly or indirectly connected to the regulation of cell 
motility (Supplementary Table 1). 
In LNT-229-rCPE cells we found by IPA an enrichment of 
differentially expressed mRNAs that are associated to the 
CDC42-, FAK-, STAT3-, TGF-β-, PAK- and integrin-
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signaling pathways, all known to regulate migration and all 
known to be involved in carcinogenesis or tumor 
progression (Figure 4.2.1, Table 4.2.1). Even though the Z-
score, an indicator of pathway activation/inactivation, did 
not reach significance, there is a tendency detectable that 
the CDC42-, TGF-β-, PAK- and integrin signalling 
cascades are less activated in LNT-229-rCPE cells. Missing 
significance in this analysis could be explained by the 
algorithm of the IPA software since this program does not 
take into consideration the literature available for glioma 
due to the high similarity of available gliomas gene profiles 
and of our glioma samples. 
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Figure 4.2.1 Canonical pathway analyses. IPA based 
analysis of differential gene expression in LNT-229-rCPE 
versus -neo cells and their association to signaling 
networks representing enriched (pValue < 0.05) canonical 
pathway considered as important in cell motility. 
 
To confirm microarray derived changes in the expression 
of motility-associated genes, we exemplarily validated 
CPE-induces changes in the expression of assorted genes 
using quantitative reverse-transcription PCR (qRT-PCR). 
Since cell motility is a complex process involving cell 
adhesion, destruction of the cellular matrix, modification of 
the cell architecture and others, we evaluated genes 
involved in different processes influencing cell motility 
(Figure 4.2.2). In LNT-229-rCPE osteopontin (OPN/SPP1), 
0         1.0       2.0       3.0      4.0       5.0        6.0
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a secreted, pro-migratory factor, was downregulated (10.1 
x down). Stanniocalcin-1 (STC1), a marker-gene for 
glioma progression and known to be a hypoxia-dependent 
migration factor in glioma, was also downregulated (1.6 x 
down) while procaherin-17 (PCDH17) which regulates 
actin dynamics and is known to inhibit metastasis and 
invasion of HCC cells, was upregulated (4.7 x up). 
Tetraspanin (CD9), known to inhibit CD26-mediated 
invasion of mesenthelioma, was upregulated (3.5 x up). 
qRT-PCR confirm the micro-array data in regard to the 
expression of enzymes involved in the destruction and 
modulation of the extracellular matrix. Additionally, a 
disintegrin and metalloprotease with thrombospondin 
motifs (ADAMTS4, 3.3 x down), N-Acetyl-Glucosamyl-
Transferase IV A (MGAT4A, 3.2 x down) the stem cell 
marker SRY-box 2 (SOX2, 2.6 x down) as well as the pro-
migratory SNAIL-family zink finger 2 protein 
(SNAI2/SLUG, 8x down) are downregulated in LNT-229-
rCPE cells. 
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Figure 4.2.2 CPE modulates the expression of motility-
associated genes. qRT-PCR of assorted genes we found to 
be differentially regulated by mRNA microarray epxression 
analysis in LNT229-rCPE vs.LNT-229-neo control cells 
and that are associated with cell motility. qRT-PCR was 
done in at least three LNT-229-rCPE or sibling neo-control 
cell clones (n>3, SEM, * p < 0.05). 
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Gene Protein 
pro/anti- 
migratory 
Fold change 
in 
microarray 
(rCPE/neo) 
Function 
Association to 
signaling pathway 
ADAMTS1 
A Disintegrin And 
Metalloproteinase 
with 
Thrombospondin 
motifs 1 
pro[90] 
2.9 x down 
(p<10
-4
) 
Metalloproteinase, contributes to 
IGFII-mediated IGF1R 
phosphorylation and cellular migration 
in glioma cells, semaphorin 3C 
cleavage induced by ADAMTS1 
promotes cell migration; marker for 
poor prognosis in glioma 
FAK[91], 
integrin[92],  
TGF-β[93] 
ADAMTS4 
A Disintegrin And 
Metalloproteinase 
with 
Thrombospondin 
motifs 4 
pro[94] 
3.3 x down 
(p<10
-11
) 
Metalloproteinase, degradation of 
aggrecan, matrix degrading enzyme 
FAK[95], 
integrin[92],  
TGF-β[96] 
ARRDC3 
Arrestin domain-
containing 3 
anti[97] 
1,5 x up 
(p<10
-4
) 
Overexpression represses cancer cell 
proliferation, migration, invasion, 
growth in soft agar and in vivo 
tumorigenicity. Downregulation has 
Integrin[97] 
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the opposite effects; controls the cell 
surface adhesion molecule, beta-4 
integrin, often epigenetically silenced 
CD9/MRP-1 Tetraspanin anti[98] 
3.5 up 
(p<10
-11
) 
Inhibits CD26 mediated enhancement 
of invasive potential of 
mesenthelioma; in glioma cells, 
knockdown of CD9 blocked PDGF 
stimulated migration 
CDC42[99], 
FAK[100], 
integrin[101], 
STAT3[102] 
CHL1/L1-
CAM2 
cell adhesion 
molecule L1-like 
pro[103, 
104] 
5.1 x down 
(p < 10
-8
) 
Overexpressed in glioma stem 
cells.L1CAM stimulates glioma cell 
motility; Slug binding to on  L1CAM 
promoters is essential for its induction 
by TGF-β 
FAK[105], 
integrin[105], TGF-
β[106] 
PTGS2/COX-2 Cyclooxygenase 2 pro[107] 
4.2 x down 
(p < 10
-6
) 
Enzyme involved in prostaglandin 
(including PGE2) biosynthesis, 
promotes glioma cell migration 
STAT3[108], 
CDC42[109], 
FAK[110], 
integrin[111], TGF-
β[112] 
CTSD Cathepsin D pro[113] 
1.7 x down 
(p < 10
-4
) 
Involved in cancer cell invasion. 
Cancer cell invasion is also induced 
by cathepsin B. Pro-cathepsin B is 
activated by cathepsin D 
CDC42[114], 
STAT3[115] 
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CTSH Cathepsin H pro[116] 
2,3 x down 
(p < 10
-4
) 
Induces glioma cell invasion, 
correlates with glioma malignancy, 
promotes hepatoma cell migration and 
invasion 
Integrin[117] 
ENPP2 Autotaxin pro[118] 
4 x down 
(p < 10
-10
) 
multifunctional phosphodiesterase, 
potent cell motility-stimulating factor in 
GBM, promotes MMP-3 production 
STAT3[119], 
CDC42[120], 
FAK[121], 
integrin[122] 
IGFBP7 
Insulin-like growth 
factor binding 
protein 7 
pro[123] 
3.3 x down 
(p<10
-5
) 
Induces migration in glioma cells, 
IGFBP7 knockdown restores TGF-β 
induced EMT 
TGF-β[124] 
MGAT4A 
N-Acetyl-
Glucosamyl-
Transferase IV A 
pro[125] 
3,2 x down 
(p<10
-9
) 
transfers GlcNAc in a specific linkage 
to N-glycans, upregulared in breast 
cancer tissue; high expression 
promotes invasion in choriocarcinoma 
Integrin[126], TGF-β 
[127] 
MGST1 
Microsomal 
Glutathione-S-
Transferase 1 
[128] 
5.4 x up 
(p<10
-12
) 
Involved in laminin-dependent 
migration in PC-12 cells, upregulated 
in glioma-derived glial progenitor cells, 
strongly downregulated in LTBP-/- 
mice 
TGF-β [129] 
MST4 member of the pro[130] 13.2 x down Involved in cell migration; promotes  
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Sterile 20 
serine/threonine 
kinase family 
(p<10
-13
) hepatocellular carcinoma epithelial-
mesenchymal transition 
PAK3 
p21 protein 
activated kinase 3 
pro[131] 
1.98 x down 
(p <  10
-5
) 
stimulate cell migration and  
anchorage-independent growth 
CDC42[132], 
FAK[133], 
integrin[134] 
PCDH17 Procadherin 17 anti[135] 
4.7 up 
(p<10
-11
) 
Inhibits cell migration and invasion of  
esophageal squamous cell carcinoma, 
silenced in many cancers, regulates 
actin dynamics; loss promotes 
metastasis and invasion in 
hepatocellular carcinoma cells 
Integrin 
PPARG 
Peroxisome 
Proliferator-
Activated Receptor 
γ 
anti[136] 
1.9 x up 
(p<10
-6
) 
PPARagonists block glioma 
motility and invasiveness 
TGF-β [137], 
STAT3[138], 
PTPRD 
Protein Tyrosine 
Phosphatase, 
Receptor Type, D 
anti[139, 
140] 
3.2 fold up 
(p<10
-7
) 
Loss in high grade GBM, 
reintroduction enhances cell adhesion 
of GBM cells, suppresses cancer cell 
migration 
 
STAT3[139] 
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PXDN Peroxidasin pro[141] 
8.7 down 
(p<10
-13
) 
regulator of cell plasticity and 
extracellular matrix remodeling; 
glioma endothelial marker gene, 
upregulated in tumor vasculature 
extracellular matrix 
 
 
Integrin[142] 
SDC2 Syndecan-2 pro[143] 
2.7 down 
(p<10
-9
) 
Promotes membrane protrusion and 
migration; involved in cell adhesion; 
induces cell migration and invasion in 
human colon and pancreatic cancer 
cells 
CDC42[144], 
FAK[145], 
integrin[143], TGF-β 
[146] 
SNAI2 Slug pro[28] 
8.0 x down 
(p < 10
-8
) 
Transcription factor involved in the 
epithelial to mesenchymal (EMT) 
transition 
STAT3[147], 
CDC42[148], 
Integrin[148], TGF-
β[149] 
SPP1 Osteopontin (OPN) pro[150] 
10.1 x down 
(p<10
-7
) 
Matricellular protein, promotes glioma 
cell migration and invasion 
 
STAT3[151], 
CDC42/Rho[152], 
FAK[153], 
Integrin[153], TGF-
β[154] 
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Table 4.2.1 Differentially regulated genes found by mRNA micro-array expression analysis and qRT-PCR 
that are known to be involved in processes regulating cell motility, and their association to motility-
modulating signaling pathways.  
Changes in expression of genes written in bold (LNT229-rCPE versus LNT-229-neo cells) were validated by 
qRT-PCR in at least three different clonal cell sublines (Figure 4.2.2). 
 
SOX2 SRY-box 2 pro[155] 
2.6 x down 
(p<10
-4
) 
Stem cell marker 
STAT3[147], TGF-
β[156] 
STC1 Stanniocalcin-1 pro[157] 
1.6 x down 
(p = 0.004) 
Secreted glycoprotein, biomarker of 
glioma progression, hypoxia-
dependent migration factor in glioma 
FAK[158],  
TGF-β[159] 
TGFBR2 
TGF-β Receptor 
Type II 
pro[160] 
1.9 x down 
(p < 10
-5
) 
Receptor for TGF-β, promotes 
migration in glioma cells 
integrin[161],FAK 
[161] 
TGF-β[160] 
ZFPM2/FOG-2 
Zinc Finger Protein, 
FOG Family 
Member 2 
pro[162] 
2.3 x down 
(p < 10
-9
) 
Involved in post-mitotic neuronal 
migration, found to interact with 
STAT3 in liver 
STAT3[163] 
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In the past years many miRNAs have been discovered that 
are involved in cancer progression or in the regulation of 
cell motility and metastasis [164-168]. By miRNA 
microarray expression analysis of LNT-229rCPE- versus 
LNT-229-neo cells, followed by IPA and miR-target gene 
analysis, we identified 8 miRNAs (FDR > 0.05) that target 
differentially expressed RNAs (Table 4.2.2). Hsa-miR-182-
5p (2.3 x up) targets SNAI2/SLUG and Hsa-miR-130a-3p 
(2.6 x down) targets PPARG and ZFPM2, both upregulated 
in LNT-229-rCPE cells. A further IPA analysis also 
demonstrates that the differentially expressed miRNAs we 
identified were also either directly or indirectly connected 
to the motility-associated signaling pathways mentioned 
above (Table 4.2.2).  
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miRNA 
Fold change of 
miRNA 
expression in 
microarray 
analysis 
(rCPE vs. neo) 
FDR 
Putative 
miRNA targets 
differentially 
regulated and 
involved in 
migration 
Fold change of target gene 
expression 
(rCPE vs. neo) 
depicted by microarray 
analysis 
Association 
to signaling 
pathways 
hsa-miR-199a-3p 
25 x up 
 (p= 1 x 10-7) 
2.23 x 10-4 
PTGS2 
 
MET 
4.2 x down  (p = 4.7 x 10-6) 
 
1.5 x down  (p = 2.2 x 10-4) 
 
 
FAK, 
Integrin, 
TGF-β, 
CDC42 
hsa-miR-182-5p 
2.3 x up  
(p = 2.9 x 10
-4
) 
2.89 x 10-2 
SNAI2[169] 
 
MITF 
8.0 x down  (p =  1.6 x 10-9) 
 
2.0 x down  (p = 4.3 x 10-5) 
 
 
FAK, PAK, 
TGF-β, 
CDC42, 
STAT3 
hsa-miR-140-5p 
3.2 x up  
(p = 1.97 x 10
-7
) 
3.27 x 10-4 
SOX2[170] 
 
TGFBR1[171] 
2.6 x down  (p =  3.2 x 10-5) 
 
1.2 x down  (p =  1 x 10-2) 
 
 
PAK, 
Integrin, 
TGF-β, 
CDC42 
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hsa-miR-130a-3p 
2.6 x down 
 (p = 3.3 x 10-4) 
3.,12 x 10-2 
PPARG[172, 
173] 
ZFPM2 
1.9 x up  (p = 2.5 x 10-7) 
 
2.3 x up  (p = 8.8 x 10-10) 
FAK, PAK, 
Integrin, 
TGF-β, 
CDC42, 
STAT3 
hsa-miR-106b-5p 
2.2 x up  
(p =2.47 10-5) 
6.6 x 10-3 
TGFBR2 1.9 x down  (p = 5 x 10-5) FAK, TGF-
β, CDC42, 
STAT3 
hsa-miR-30e-3p 
4 x up  
(p = 4.2 x 10
-4
) 
3.5 x 10-2 
 
WDR44 1.8 x down  (p = 9.5 x 10-6) Integrin, 
TGF-β 
hsa-miR-25-3p 
2.2 x up  
(p = 1.7 x 10
-5
) 
5.57 x 10-3 
 
FBXW7 1,6 x down (p = 6,5 x 10-5) FAK, PAK, 
Integrin, 
TGF-β, 
CDC42, 
STAT3 
hsa-let-7d-5p 
1.5 x down  
p = 1.3 x 10-4) 
1.56 x 10-2 
 
KRAS 
 
ITGB3 
1.4 x up     (p = 4.5 x 10-5) 
 
1.8 x up     (p = 3 x 10-5) 
FAK, PAK, 
Integrin, 
TGF-β, 
CDC42, 
STAT3 
Table 4.2.2 miRNA and their putative targets that are differentially expressed in LNT-229-rCPE versus 
LNT-229-neo cells. 
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4.3 CPE regulates the expression of 
SNAI2/SLUG 
In the microarray expression analysis, and validated by 
qRT-PCR, we have found SNAI2/SLUG, known to be a 
pro-migratory and pro-invasive transcription factor in 
epithelial tumors, as one prominent mRNA being 
downregulated in LNT-229-rCPE cells. For this we tested 
whether this is also true for SLUG protein. Reduced 
amounts of SLUG protein were detectable in all rat and 
human CPE-overexpressing established glioma cell lines as 
well as in the low passage primary glioma cells we tested 
(Figure 4.3.1). Consistently, in Tu-140 cells, showing 
higher basal CPE expression, but no basal SNAI2/SLUG 
expression, SNAI2/SLUG was re-expressed at both mRNA 
and protein level after siRNA-mediated knockdown of CPE 
(Figure 4.3.2, this experiment was performed by E. Ilina, 
Goethe University, Frankfurt).  
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Figure 4.3.1 SLUG expression in CPE-overexpressing 
GBM cell lines. Immunoblot detection of CPE and SLUG 
in CPE-overexpressing and control LNT-229, T98G, LN-
308 and Tu-132 cells. Tubulin was used as a loading 
control. (n = 3, one representative experiment is shown). 
  
LNT-229   LNT-229 T98G        LN-308       Tu-132  
CPE
SLUG
Tubulin
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Figure 4.3.2 SLUG expression in TU-140 primary 
glioma cells after siRNA mediated knockdown of CPE. 
A. qRT-PCR analysis of CPE and SLUG mRNA in Tu-140 
cells 48 h after siRNA transfection (si-NT, no-target 
siRNA; n=3, SD) B. Immunoblot detection of SLUG and 
CPE protein expression in Tu-140 cells 48 h or 72 h after 
siRNA-mediated knockdown of CPE. (n=3, one 
representative experiment is shown). Experiments 
performed by E. Ilina, Goethe University, Frankfurt. * p < 
0,05. 
 
We therefore tested whether glioma cell migration is 
modulated by SNAI2/SLUG. Adenovirus-based transient 
overexpression of SLUG induces migration whereas 
siRNA-mediated knockdown of SNAI2/SLUG reduces 
glioma cell migration (Figure 4.3.3).  
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Figure 4.3.3 SLUG expression positively correlates with 
glioma cell migration. A. qRT-PCR of SLUG mRNA in 
LNT-229 and Tu-132 cells 48h after adenoviral infection 
with Ad-SLUG-GFP or Ad-EGFP. B. Migration of glioma 
cells infected as in A, analyzed with transwell migration 
chambers (FC, fold change; n=3, SEM). C. qRT-PCR of 
SLUG mRNA in glioma cells 48h after siRNA transfection 
with either SLUG (si-SLUG) or EGFP (si-EGFP) specific 
siRNA. The dashed line indicates the level of SLUG 
mRNA in siEGFP-transfected cells. D. Migration of glioma 
cells after siRNA-mediated knockdown of SLUG as 
described in C, analyzed with transwell migration 
chambers. The dashed line represents the amount of 
migrated cells in si-EGFP transfected cells (n=3, SEM). 
0.0
1.0
2.0
3.0
4.0
LNT-229 Tu-132
0
100
200
300
400
LNT-229 Tu-132S
L
U
G
 m
R
N
A
(F
C
)
LNT    T 2
1.0
400
300
0
50
100
150
200
LNT-229 Tu-132
M
ig
ra
te
d
 c
e
lls
 (
%
) *
*
0
25
50
75
100
*
***
**
**
M
ig
ra
te
d
c
e
lls
(%
)
s
i-
S
L
U
G
/s
i-
E
G
F
P
Ad-EGFP
Ad-SLUG
Ad-EGFP
Ad-SLUG
A B
C D
S
L
U
G
 m
R
N
A
(F
C
)
s
i-
S
L
U
G
/s
i-
E
G
F
P
 
0
25
50
75
100
*
***
**
**
0.0
0.2
0.4
0.6
0.8
1.0
106 
 
It has been recently described that elevated SNAI2/SLUG 
correlates with the expression or activity of matrix 
metalloproteinases in several cancers [174]. Reduced 
expression of MMP-2 was detectable in LNT-229 and 
T98G cell lines that basically express MMP-2. MMP-2 is 
known to be activated by a complex containing MT1-
MMP/MMP-14 and TIMP-2 [175]. With the exception of 
LN-308 cells, reduced levels of MT1-MMP/MMP-14 and 
TIMP-2 were detected in CPE-overexpressing cell lines 
(Figure 4.3.4). 
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Figure 4.3.4 CPE modulates MMPs levels. 
Immunoblot detection of MMP-2, TIMP-2 and MMP-14 in 
CPE-overexpressing and control LNT-229, T98G, Tu-132 
and LN-308 cells. Values indicates the change in protein 
expression (MMP-2, n=2; TIMP-2, n=2; MMP-14, n=3) 
normalized to GAPDH for cytoplasmic proteins or to 
Ponceau S staining for secreted proteins.  
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4.4 The effects of CPE on the expression of 
SLUG and on glioma cell migration are 
transmitted by ERK1/2 
It has been shown in hippocampus neurons [70] and in 
HCC cells [78] that CPE acts through ERK1/2. Therefore 
we tested whether ERK1/2 phosphorylation was altered in 
both rat and human CPE-overexpressing cells to verify if 
this applies to glioma cells, too. We found enhanced 
ERK1/2 phosphorylation in LNT-229 and Tu-132 CPE-
overexpressing cells (Figure 4.4.1).  
 
Figure 4.4.1 Overexpression of CPE is paralleled by 
enhanced ERK1/2 phosphorylation. Immunoblot 
detection of P-ERK1/2 and total ERK1/2 in CPE-
overexpressing and control LNT-229 and Tu-132 cells. 
Values indicate the upregulation of P-ERK1/2 (signal 
intensity P-ERK1/2 / ERK1/2; n=3, one representative 
experiment is shown, * p < 0.05).  
P-ERK1/2
ERK1/2
Tubulin
1          7.5 *            1           2.15*             1       4.57          0        0              1          1.1       
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To verify whether ERK1/2 activation is at least partially 
responsible for CPE-mediated SLUG downregulation, we 
used the MEK inhibitor U0126 to inhibit ERK1/2 activity. 
SLUG expression was increased more prominently in 
U0126-treated CPE-overexpressing cells (Figure 4.4.2 B). 
In accordance, U0126 abolished the anti-migratory effects 
of CPE. Migration in CPE-overexpressing cells treated 
with U0126 reaches the basal level of migration of the 
respective control cells in both LNT-229 (either rat ot 
human) cells and in Tu-132 primary cells (Figure 4.4.2 
C,D), while U0126 did not induce significant changes in 
control cells.  
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Figure 4.4.2 U0126 abolished CPE-mediated SLUG 
downregulation and induces cell migration. 
A Immunoblot detection of P-ERK1/2 in LNT-229 and Tu-
132 CPE-overexpressing and control cells treated with 
U0126 (10 µM, 24 h; n=3, one representative immunoblot 
is shown). B Immunoblot detection of SLUG in CPE-
overexpressing and control LNT-229 and Tu-132 cells 
cultured in the absence or presence of U0126 (10 µM, 24 h; 
n=3, one representative immunoblot is shown). C,D Cell 
migration was analyzed by the scratch assay (C) and 
transwell migration assay (D) in rCPE-overexpressing and 
control neo LNT-229 (C) or in human CPE-overexpressing 
and control LNT-229 and Tu-132 cells (D) cultured in the 
absence (mock) or presence of U0126 (10 µM; n=3, SEM, 
* p < 0,05). 
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We were also interested to determine the upstream cell 
surface receptor by which CPE transmits its function into 
the intracellular compartment. Since it is known that EGFR 
phosphorylation is one main activator of ERK1/2 [176], we 
investigated whether sCPE could influence the 
phosphorylation and therefore activity of the EGFR. For 
this we cultivated LNT-229 cells in conditioned medium 
derived from control or CPE-overexpressing LNT-229 
(either rat or human).  We did not found any changes in P-
EGFR after cultivation of the cells in sCPE-containing 
medium in both models tested, indicating that activation of 
the EGFR is not the responsible for enhanced ERK1/2 
phosphorylation in CPE-overexpressing cells (Figure 
4.4.3). 
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Figure 4.4.3 sCPE does not lead to enhanced 
phosphorylation of the EGFR. 
Immunoblot detection of P-EGFR and total EGFR in LNT-
229 cells cultivated for increasing time periods in 
conditioned medium generated from ctrl or CPE-
overexpressing LNT-229 cells either rat or human CPE 
(n=2, one single experiment is shown). 
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4.5  CPE mediated downregulation of SLUG 
occurs independent from STAT3 
It is known that SLUG expression can be also regulated by 
the activation of STAT3. Since many mRNAs we found to 
be differentially expressed in LNT-229-rCPE cells are 
associated to the STAT3 signaling pathway, we also 
analyzed STAT3 phosphorylation. 
Reduced protein levels of P-STAT
S727 
were only detectable 
in
 
LNT-229-rCPE cells, but in none of the human CPE 
overexpressing cell lines indicating either a clonal effect in 
LNT-229-rCPE cells or a species-specific effect of rat CPE 
(Figure 4.5.1 A). STAT3 inhibition using the STAT3 
inhibitor S3I-201 reduced migration in LNT-229-neo cells 
but had no further effect on cell migration in LNT-229-
rCPE cells (Figure 4.5.1 C). 
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Figure 4.5.1 Effects of CPE on the phosphorylation of 
STAT3. A Immunoblot detection of P-STAT3
S727
and total 
STAT3 in rat or human CPE-overexpressing and control 
glioma cells. Values indicate the changes in the signal 
density of P-STAT3 compared to total STAT3. (n=3, one 
representative experiment is shown). B Immunoblot 
detection of P-STAT3 in LNT-229 rCPE-overexpressing 
and control neo cells treated 24h with S3I-201 (10 µM). 
(n=3, one representative immunoblot is shown). C Cell 
migration was analyzed using the scratch migration assay 
in rCPE-overexpressing and control neo LNT-229 cells  
treated with or without (mock) S3I-201 (10 µM; n=3, 
SEM; *p< 0,05).  
LNT-229                     LNT-229 T98G        LN-308        Tu-132
1         0.9              1         1.2            1         1.7           1         2.2
P-STAT3
STAT3
Tubulin
1      0.3
P-STAT3
STAT3
GAPDH
- +        - +      S3I-201
LNT-229     
neo rCPE
P-STAT3
STAT3
Tubulin
LNT-229      
*
0
20
40
60
80
100
120
neo rCPE 
m
ig
ra
te
d
 c
e
ll
s
 %
mock S3I-201
A
B C
115 
 
4.6 Effects of CPE on glioma therapeutic 
treatment options 
Despites all efforts that have been ventured in GBM 
therapy research in the last decades, the median patient 
survival is still short. Therefore, novel adjuvant treatment 
options that can be used in parallel to the standard therapy 
(chemoradiotherapy) are necessary. In this regard we tested 
the effects of standard GBM therapy (irradiation and TMZ 
chemotherapy), if used in combination with the 
overexpression of CPE. Using the colony formation assay 
(Figure 4.6.1), we detected the outgrowth of glioma cell 
colonies from single cells, which is supposed to be the 
mechanism behind tumor recurrence after single cells 
escape after therapy. As shown in Figure 4.6.1, the number 
of colonies derived from CPE-overexpressing cells was 
lower compared to control neo cells and it was further 
reduced when cells where treated with TMZ and exposed to 
radiation, indicating that (at least rat) CPE overexpression 
alone reduces the clonal survival of glioma cells. Besides, 
CPE works in synergy with GBM standard therapy. 
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Figure 4.6.1 Effects of CPE on colony formation.  
Colony formation assay in LNT-229-neo control and LNT-
229-rCPE-overexpressing cells pre-treated with or without 
TMZ and/or irradiation (n=4, SD, * p < 0.05, *** p < 
0.005).  
0.0
0.2
0.4
0.6
0.8
1.0
1.2
neo rCPE 2 Gy TMZ (1 
μM)
2 Gy + 
TMZ (1 
μM )
rCPE + 2 
Gy +  
TMZ (1 
μM)
calc. 
Add.
s
u
rv
iv
a
l 
ra
te
TMZ
(1 µM)
rCPE +
2 Gy +
TMZ
(1 µM)
 
TMZ
(1 µM)
*
*
*
*
*
* *
*
*
*
*
117 
 
In order to consider a translational application of CPE, we 
evaluated whether in vivo the CPE-mediated anti-migratory 
effect or reduced clonal survival we observed in vitro was 
associated to the survival of glioma bearing mice. For this 
we implanted control or CPE-overexpressing LNT-229 
(either rat or human), and LN-308-ctrl or LN-308-CPE 
cells into the right striatum of NMRI nude mice. We 
monitored the influence of tumor development and growth 
by weight loss and neurological symptom. Mice were 
sacrificed if neurological symptoms and/or cachexia were 
observed and Kaplan-Meier survival curves were produced 
(Figure 4.6.2). Mice harboring tumors derived from CPE-
overexpressing cells showed prolonged survival compared 
to mice harboring control tumors. The prolongation in 
survival was significant for LNT-229-CPE tumors (both rat 
and human CPE), while only a trend was observed in LN-
308 tumors. We exemplarily analyzed tumor growth by 
MRI in 2 animals per group at different time points after 
tumor cell implantation (Figure 4.6.3), but did not observe 
any substantial difference in the tumor size between mice 
bearing control tumors or CPE-overexpressing tumor. Due 
to the small group size, it is only speculative to say that 
CPE did not influence tumor growth. 
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Figure 4.6.2 Kaplan-Meier survival curves of GBM 
bearing NMRI nude mice. A. Survival of animals bearing 
LNT-229-rCPE or LNT-229-neo xenografts. (summary of 
two independent experiments, n=10); B. LNT-229-CPE or 
LNT-229-ctrl (n=6); C. LN-308-CPE or LN-308-ctrl 
xenografts (n=7).  
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Figure 4.6.3 MRI of mice harboring LNT-229-rCPE or 
LNT-229-neo tumors 
MRI images of mice brains at different time points after 
tumor cells implantation. Manually calculated tumor 
volumes are indicated below the images. Arrows point to 
the tumors locations. 
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5. DISCUSSION 
 
Glioblastoma is the most malignant brain tumor, mainly 
because of its infiltrative growth, its immunosuppression, 
its resistance towards cells death but also because of its 
ability to adapt to the tumor microenvironment. One 
mechanism which includes both adaptation and invasion 
actuated by glioma cells is the switch between the 
proliferative or migratory phenotype depending on the 
circumstances, leading to the “Grow or Go” behavior of 
glioma cells. It has been described by Höring et al. [51] 
that one of the factors modulating this process is a secreted 
version of Carboxypeptidase E. In particular, in a rat CPE-
overexpressing model, sCPE enhanced glioma cell 
proliferation whereas migration was reduced. 
Main foci of this thesis were to test whether CPE is a 
“Grow or Go” switch factor in GBM and how CPE 
transmits its function. Therefore we used LNT-229 rat 
CPE-overexpressing clonal cell lines generated by Höring 
[51] as well as produced stable human CPE-overexpressing 
primary and established GBM cell lines. 
The pro-proliferative role of CPE has been investigated in 
other cancer entities, like CRC, in which CPE-mediated 
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downregulation of p21
WAF1
 led to enhanced proliferation 
[79]. For glioma cells, increased proliferation was only 
detectable in LNT-229-rCPE cells as previously described 
by Höring [51], while this effect was absent or only 
marginal in human CPE-overexpressing glioma cells 
(Figure 4.1.3), even though the cell cycle regulator p21
WAF1
 
was downregulated in all (both rat and human) CPE-
overexpressing cells (Figure 4.1.2). On the contrary, cell 
migration was significantly reduced in all (rat and human) 
CPE-overexpressing primary cells as well as in established 
GBM cell lines. Consistently, siRNA-mediated 
downregulation of CPE in highly CPE-expressing Tu-140 
glioma primary cells induced cell motility (Figure 4.1.4).  
These data indicate that CPE exert its function on GBM 
cells through the modulation of cell migration whereas the 
effects of CPE on proliferation seemed to be species-
specific.  
Rat and human CPE are highly homologous with a 96% 
identity and 98% similarity in the amino acid (AA) 
sequence and even a total conservation of the Zn-
carboxypeptidase domain. Therefore the enzymatic activity 
is not different between rat and human CPE [57]. Besides, 
a correct procession and maturation of CPE might be 
conserved for both species, since the penta-arginine 
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sequence (RRRRR42) also shows 100% homology. 
Changes in the AA sequence occur in proximity of the 
prohormone sorting signal binding site. One could 
speculate that the latter might play a major role in the 
functional differences between rat and human CPE and 
make the prohormone sorting signal binding site as the 
putative domain responsible for different effects of rat and 
human CPE on cell growth. 
In this study we focused to evaluate how CPE transmits its 
anti-migratory function in glioma cells. Our findings as 
well as knowledge from the literature suggest that CPE 
modulates, beside the ERK1/2, also the AKT and/or WNT 
signaling pathway as it has been described for other tumor 
and non-tumor cells such as HCC, CRC, 
pheochromocytoma cells or hypocampal neurons [70, 78, 
177, 178]. However, which pathways or which factors are 
involved in CPE-mediated effects on GBM cell migration 
has not been elucidated in detail. In this regard, changes in 
the expression of motility-associated genes have been 
analyzed as well as signaling cascades that are modulated 
by CPE have been investigated.  
Using mRNA and miRNA microarray chip technology in 
LNT-229-rCPE cells and LNT-229-neo cells, followed by 
quantitative RT-PCR validation of mRNA expression and 
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IPA, we investigated CPE-mediated changes in gene 
expression and its impact of motility-associated signaling 
cascades. We found that 1065 mRNA were differentially 
expressed and at least 100 genes were either directly or 
indirectly connected to the regulation of cell motility 
(Supplementary Table 1). In addition, eight miRNA, in 
combination with their reverse expressed targets, are 
differentially regulated in LNT-229-rCPE cells (Table 
4.2.2). Many of the motility-associated genes and all 
miRNAs showed a connection to motility-associated 
pathways integrating TGF-β, CDC42, PAK, FAK, STAT3 
and integrin. IPA demonstrated an enrichment of 
differentially expressed mRNAs associated to the above 
mentioned signaling cascades (Figure 4.2.1, Table 4.2.2).  
After intensive validation of microarray data by qRT-PCR 
we identified genes known to regulate cell motility that are 
significantly differentially expressed (Figure 4.2.2): 
procaherin-17 (PCDH17, 4.7 x in LNT-229-rCPE) inhibits 
cell migration and invasion of esophageal squamous cell 
carcinoma, it is silenced in many cancers and regulates 
actin dynamics [135]. Stanniocalcin-1 (STC1, 1.6 x down 
in LNT-229-rCPE), a secreted glycoprotein, is a biomarker 
of glioma progression and it is involved in hypoxia-
dependent migration in glioma [157]. Osteopontin 
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(OPN/SPP1, 10.1 x down in LNT-229-rCPE), a 
matricellular protein, promotes glioma and stem cell 
migration and invasion through a variety of pathways [150-
154], and A disintegrin and metalloprotease with 
trombospondin motifs (ADAMTS4, 3.3 x down in LNT-
229-rCPE) and N-Acetyl-Glucosamyl-Transferase IV A 
(MGAT4A, 3.2 x down in LNT-229-rCPE) are involved in 
invasive processes. ADAMTS4 leads to the degradation of 
aggrecan. In an oligodendroglioma model, ADAMTS4 it is 
responsible for cell invasion through aggrecan-rich 
extracellular matrices [179] whereas MGAT4A transfers a 
N-acetylglucosamine (GlcNAc) group to N-glycans, this 
resulting in increased GlcNAc-N-glycan branches on 
integrin β1 and promotion of invasion of choriocarcinoma 
cells [125]. 
One prominent downregulated gene is snail family zink 
finger 2 (SNAI2/SLUG, 8x down in LNT-229-rCPE), 
which has been linked to the more malignant, more 
invasive and migratory mesenchymal phenotype of gliomas 
as well as to pro-tumorigenic processes of many other 
cancers [28, 180, 181]. SNAI2/SLUG expression is either 
directly or indirectly regulated by CPE, since it is 
downregulated in all CPE-overexpressing primary and 
established GBM cells (Figure 4.3.1), whereas 
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downregulation of CPE by siRNA led to enhanced SLUG 
expression in Tu-140 cells (Figure 4.3.2). SNAI2/SLUG 
modulates cell migration through different mechanisms. 
After TGF-β administration, SLUG binds to both 
promoters of the cell adhesion molecule with homology 
gene (CHL/L1-CAM-2; 5.1 x down in LNT-229-rCPE) this 
way inducing L1-CAM expression [106]. L1-CAMs are 
described to enhance glioma cell motility and invasion and 
correlate with FAK activity [182]. In glioma cells, CPE-
mediated anti-migratory effects seemed to be directly 
dependent on SLUG, since exogenous overexpression of 
SLUG significantly enhanced migration whereas its 
knockdown significantly mitigated glioma cell migration to 
about 60% of the control, the same percentage of reduction 
we observed by CPE overexpression. This suggests that the 
CPE-mediated downregulation of SLUG might be a central 
component to reduce cell motility in CPE-overexpressing 
glioma cells (Figure 4.3.3).  
During glioma invasion different MMPs can be activated to 
destroy the extracellular matrix and make it more 
accessible for invading cells. Therefore we tested MMP 
expression and found reduced levels of MMP-2, MT1-
MMP/MMP-14 and TIMP-2 in those human CPE-
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overexpressing glioma cells that express these enzymes 
(Figure 4.3.4).  
In a recent study in breast cancer cells, metabolic changes 
induced during epithelial-to-mesenchymal transition 
(EMT) have been elucidated [183]. EMT-derived breast 
cancer cells show enhanced expression EMT proteins 
including SNAI2/SLUG. Besides, they display an increase 
in aerobic glycolysis at the expenses of the pentose 
phosphate pathway (PPP) and glycogen synthesis. This 
metabolic switch is mediated by increased glucose uptake 
and lactate production, through the upregulation of glucose 
transporters (GLUT3), lactate dehydrogenases (LDHA) and 
lactate transporters (MCT4). In a parallel study (data in 
publication) in collaboration with Prof. Dr. Michel 
Mittelbronn and Elena I. Ilina (Neuropathology, Goethe-
University Frankfurt), we investigated the metabolic 
changes in CPE-overexpressing GBM cells, the same cells 
that showed lower levels of SLUG and lesser cell 
migration. We found that GLUT3, LDHA and MCT4 
expression was reduced in CPE-overexpressing cells and 
observed a shift to the utilization of the PPP pathway, 
instead of using aerobic glycolysis. However, whether 
these changes are caused directly by CPE or by the CPE-
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mediated downregulation of SNAI2/SLUG has not been 
investigated so far. 
Another purpose of this study was to decipher the signaling 
pathway(s) by which CPE mediates its effects on GBM cell 
motility. IPA analysis and literature research performed on 
the differentially regulated genes, as mentioned before, 
highlights the putative involvement of TGF-β, CDC42, 
PAK, FAK, STAT3 and integrin signaling pathways in the 
anti-migratory function of CPE. In hippocampal neurons 
[70] and HCC cells [78], CPE acts through ERK1/2. 
Therefore we decided to focus on the ERK1/2 pathway to 
verify if this applies on glioma cells, too. We analyzed if 
ERK1/2 activation affects SLUG expression and modulates 
GBM cell migration. We observed enhanced ERK1/2 
phosphorylation in both rat and human CPE-
overexpressing LNT-229 and in Tu-132-CPE primary 
GBM cells, indicating that enhanced activation of ERK1/2 
in CPE-overexpressing cells correlates with reduced SLUG 
levels and lesser migration (Figure 4.4.1). Typically, the 
ERK1/2 pathway is associated with increased migration, 
especially in the context of EMT that follows the 
EGFR/Src/ERK/SLUG signaling axis [184]. 
Controversially it has been described that ERK1/2 
inhibition by U0126 did not cause any changes on cell 
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migration in some glioma cell lines [185, 186]. Indeed, we 
detected no major changes in glioma cell migration after 
inhibition of ERK1/2 activation glioma control cells. 
Interestingly, inhibition of CPE-mediated ERK1/2 
phosphorylation with U0126 in CPE-overexpressing cells 
was able to abolish the CPE-mediated downregulation of 
SNAI2/SLUG as well as the CPE-mediated reduction of 
migration and restore the same amount of SLUG and 
migration we observed in control cells (Figure 4.4.2).  
We were interested in identify upstream receptors that 
might be responsible for the sCPE mediated 
phosphorylation of ERK1/2. First our collaborator E. I. 
Ilina analyzed the phosphorylation of a panel of surface 
receptors using a membrane-base assay and found slightly 
elevated levels of P-EGFR in LNT-229-rCPE cells. 
However, immunoblot analyses done in our lab to show 
EGFR phosphorylation in parental glioma cells treated with 
sCPE-containing cell supernatants generated from CPE-
overexpressing cells did not confirm these results (Figure 
4.4.3). 
Recent studies showed that ERK1/2 can also regulate the 
P-STAT3
S727
, this way modulating STAT3 tyrosine 
phosphorylation which is necessary for its nuclear transport 
and DNA binding as a transcription factor [190]. Since 
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many of the differentially expressed genes, including 
SNAI2/SLUG, are targets of the STAT3 pathway, we also 
analyzed STAT3 phosphorylation. STAT3
S727
 
phosphorylation was only reduced in LNT-29-rCPE cells. 
No changes in P-STAT
 S727 
were observed in human-CPE 
overexpressing cells. Although STAT3 inhibition was able 
to abolish the anti-migratory effects of CPE effects in 
LNT-229-neo control cells, there was no effect on the 
migration in LNT-229-rCPE cells (Figure 4.5.1), 
suggesting that reduced P-STAT
 S727 
in LNT-229-rCPE 
cells was either a clonal effect or was a result of a species-
specific function of CPE.  
Our data indicate that CPE might act through a still 
unknown receptor or binding partner that leads to 
activation or inhibition of several signaling cascades. One 
of these signaling pathways integrates the activation of 
ERK1/2 to ultimately reduce SLUG expression and 
migration of GBM cells. It will be a challenge for the 
future to identify the upstream factors that functionally lead 
to the activation of ERK1/2, finally resulting in an altered 
expression of motility-regulating genes in CPE expressing 
glioma cells. 
Besides, considering all known and putative functions of 
CPE, it could be suggested that also other mechanisms 
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could be involved in its anti-migratory effect. It has been 
recently described that CPE obstructs the β-catenin 
pathway, inhibits the secretion and activity of Wnt3a and 
forms aggregates with it into non soluble cellular fraction 
[80]. However, the role of CPE in Wnt3a-mediated cell 
migration has not been investigated so far. Taking into 
account the enzymatic activity of CPE and its role in 
protein sorting, and also knowing that sCPE is not active in 
the extracellular space due to a neutral pH in this 
compartment, it is still possible that during the secretion 
process CPE modulates the vesicles contents leading to a 
rearrangement of the secretome that might contain 
secretable, motility-regulating factors.  
Another hypothesis how CPE can also transmit its anti-
migratory effects is the knowledge that, during or after 
exocytosis, membrane bound CPE (mCPE), by interaction 
with ARF6, is recycled back to the TGN [67]. ARF6 
mediates Rac1 activation and actin remodeling, necessary 
for glioma invasion. Inhibition of ARF6 in GBM cells 
reduces cell migration [191]. By CPE overexpression also 
the mCPE levels might be elevated. Therefore ARF6 is 
recruited by mCPE and it is not able anymore to exert its 
pro-migratory function.  
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Considering that CPE, among 311 proteases, is the only 
protease that has been found to be downregulated in GBM 
specimens [192], we decided to investigate the role of CPE 
from a more clinical point of view and to evaluate whether 
the anti-migratory effects induced by CPE we observed in 
vitro is associated to the survival of GBM bearing mice in 
vivo.  
We evaluated whether CPE influences the effects of GBM 
standard therapy in vitro and found that CPE acts in 
synergy with GBM standard therapy regarding the 
reduction to the outgrowth of tumor cells clones from 
single tumor cell (Figure 4.6.1). 
This makes sCPE a possible marker protein to predict the 
outcome of glioma radiochemotherapy in GBM patients or 
even a putative candidate for an adjuvant treatment of 
GBM. In orthotopic GBM mouse models we showed that 
mice harboring tumors derived from CPE-overexpressing 
cells lived longer than mice harboring control tumors 
(Figure 4.6.2). This indicates that CPE-overexpressing 
glioma cells produce either lesser infiltrative/invasive 
growing tumors or that a lesser amount of cells expressing 
CPE survive or grow up if they settle, after implantation, as 
single cells in the brains micro-milieu.  
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6. CONCLUSIONS 
 
The data presented in this study clarify some of the 
mechanisms by which CPE, and especially sCPE, mitigates 
GBM cell migration. In particular we identified 
SNAI2/SLUG and the ERK1/2 pathway, among other cell 
motility-associated genes and cascades, to be mediators of 
the anti-migratory effects of CPE. In addition, we proved 
that CPE provides a beneficial role by enhancing the effect 
of radiochemotherapy at least in vitro. In a mouse glioma 
model, overexpression of CPE prolonged the survival in 
vivo.  
Nevertheless, further investigation will be necessary to 
completely understand the mechanism of action of CPE 
and the feasibility to use this protein as a therapeutic agent 
in the treatment of malignant glioma.  
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7. SUPPLEMENTARIES  
 
Supplementary Table 1: Differential expression of 100 
cell motility-associated genes in LNT-229-rCPE versus 
LNT-229-neo control cells detected by microarray 
expression analysis. 
UPREGULATED GENES 
Gene Protein 
Fold 
change 
(rCPE 
vs neo) 
p-value FDR 
IL15 interleukin 15 5.46 1.09E-10 1.19E-07 
MGST1 Microsomal 
Glutathione-S-
Transferase 1 
5.42 5.22E-13 2.52E-09 
PCDH17 protocadherin 17 4.67 1.81E-11 3.82E-08 
CD9 CD9 molecule 3.53 4.63E-11 6.42E-08 
DACH1 dachshund 
homolog 1 
(Drosophila) 
3.49 2.62E-10 2.26E-07 
ALX1 ALX homeobox 1 3.40 1.56E-09 8.29E-07 
SCG2 secretogranin II 3.08 5.22E-06 4.70E-04 
LIN28B lin-28 homolog B 
(C. elegans) 
2.81 5.90E-09 2.36E-06 
MSR1 macrophage 
scavenger 
receptor 1 
2.60 2.86E-08 8.07E-06 
PTPRD protein tyrosine 
phosphatase, 
receptor type, D 
2.59 1.26E-10 1.35E-07 
PAPPA pregnancy-
associated 
plasma protein A, 
pappalysin 1 
2.52 1.35E-06 1.65E-04 
134 
 
CCL2 chemokine (C-C 
motif) ligand 2 
2.36 7.81E-05 3.67E-03 
BDKRB2 bradykinin 
receptor B2 
2.34 2.02E-05 1.31E-03 
ZFPM2 zinc finger protein, 
multitype 2 
2.30 8.88E-10 5.45E-07 
EPS8 epidermal growth 
factor receptor 
pathway substrate 
8 
2.23 1.70E-05 1.14E-03 
CTSK cathepsin K 2.22 1.05E-07 2.16E-05 
FOXM1 forkhead box M1 2.22 1.29E-04 5.37E-03 
EREG epiregulin 2.18 2.45E-06 2.66E-04 
UBD ubiquitin D 2.10 7.48E-05 3.54E-03 
MGP matrix Gla protein 2.10 9.87E-09 3.55E-06 
BHLHE4
1 
basic helix-loop-
helix family, 
member e41 
2.05 1.80E-06 2.06E-04 
SERPINB
5 
serpin peptidase 
inhibitor, clade B 
(ovalbumin), 
member 5 
2.01 1.39E-07 2.73E-05 
TNFAIP8 tumor necrosis 
factor, alpha-
induced protein 8 
2.00 8.21E-07 1.10E-04 
PODXL podocalyxin-like 1.98 1.82E-08 5.65E-06 
PRKCD protein kinase C, 
delta 
1.96 2.65E-06 2.84E-04 
BMP2 bone 
morphogenetic 
protein 2 
1.94 6.13E-05 3.04E-03 
PPARG peroxisome 
proliferator-
activated receptor 
gamma 
1.89 2.57E-07 4.45E-05 
ITGB3 integrin, beta 3 
(platelet 
glycoprotein IIIa, 
antigen CD61) 
1.87 3.07E-05 1.81E-03 
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FNBP1L formin binding 
protein 1-like 
1.86 7.19E-05 3.43E-03 
KDM5A lysine (K)-specific 
demethylase 5A 
1.73 5.48E-06 4.86E-04 
GBP1 guanylate binding 
protein 1, 
interferon-
inducible 
1.73 4.30E-05 2.34E-03 
TPM1 tropomyosin 1 
(alpha) 
1.70 1.78E-06 2.04E-04 
LOXL2 lysyl oxidase-like 
2 
1.68 5.40E-07 7.94E-05 
SERPINA
5 
serpin peptidase 
inhibitor, clade A 
(alpha-1 
antiproteinase, 
antitrypsin), 
member 5 
1.67 6.89E-07 9.75E-05 
DNAJB4 DnaJ (Hsp40) 
homolog, 
subfamily B, 
member 4 
1.67 3.68E-06 3.70E-04 
CSF2RA colony stimulating 
factor 2 receptor, 
alpha 
1.64 6.83E-06 5.72E-04 
ZEB1 zinc finger E-box 
binding homeobox 
1 
1.63 6.59E-05 3.21E-03 
MFI2 antigen p97 
(melanoma 
associated)  
1.63 1.53E-06 1.82E-04 
KCNN3 potassium 
intermediate/small 
conductance 
calcium-activated 
channel, 
subfamily N, 3 
1.62 2.01E-05 1.31E-03 
SLC12A6 solute carrier 
family 12 
(potassium/chlorid
e transporters), 
member 6 
1.62 3.96E-06 3.87E-04 
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PTPRF protein tyrosine 
phosphatase, 
receptor type, F 
1.57 6.96E-06 5.81E-04 
INADL InaD-like 
(Drosophila) 
1.57 1.07E-04 4.86E-03 
NOTCH2 notch 2 1.56 9.16E-06 7.09E-04 
ARRDC3 arrestin domain 
containing 3 
1.55 7.88E-05 3.69E-03 
FERMT1 fermitin family 
member 1 
1.55 2.30E-05 1.44E-03 
PRKAR2
A 
protein kinase, 
cAMP-dependent, 
regulatory, type II, 
alpha 
1.54 1.83E-04 7.01E-03 
CSPG4 chondroitin sulfate 
proteoglycan 4 
1.53 3.57E-06 3.60E-04 
NFKBIA nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-
cells inhibitor, 
alpha 
1.53 5.81E-05 2.92E-03 
GAB1 GRB2-associated 
binding protein 1 
1.52 7.82E-06 6.28E-03 
TGFA transforming 
growth factor, 
alpha 
1.51 5.46E-06 4.86E-04 
    
DOWNREGULATED GENES       
Gene Protein 
Fold 
change 
(rCPE 
vs neo) 
p-value FDR 
MST4 serine/threonine 
protein kinase 
MST4 
-13.23 1.38E-14 1.59E-10 
SPP1 secreted 
phosphoprotein 1 
-10.18 7.60E-08 1.71E-05 
PXDN perxoidasin -8.73 1.61E-13 1.21E-09 
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SNAI2 snail homolog 2 
(Drosophila) 
-8.04 1.68E-09 8.74E-07 
CHL1 cell adhesion 
molecule with 
homology to 
L1CAM (close 
homolog of L1) 
-5.15 9.35E-09 3.42E-06 
A2M alpha-2-
macroglobulin 
-4.58 7.38E-07 1.02E-04 
MAP7D3 MAP7 domain 
containing 3 
-4.32 4.34E-09 1.82E-06 
PTGS2/C
OX2 
prostaglandin-
endoperoxide 
synthase 2 , 
cyclooxigenase-2 
-4.20 4.70E-06 4.32E-04 
ENPP2 ectonucleotide 
pyrophosphatase/
phosphodiesteras
e 2 
-4.06 3.87E-10 2.90E-07 
GDF15 growth 
differentiation 
factor 15 
-3.62 1.99E-04 7.44E-03 
DKK1 dickkopf 1 
homolog 
(Xenopus laevis) 
-3.42 2.38E-04 8.55E-03 
IGFBP7 insulin-like growth 
factor bindung 
protein 7 
-3.35 1.30E-06 7.78E-05 
ADAMTS
4 
ADAM 
metallopeptidase 
with 
thrombospondin 
type 4 
-3.32 2.13E-11 3.88E-08 
MGAT4A N-Acetyl-
Glucosamyl-
Transferase IV A 
-3.23 1.64E-10 1.61E-07 
LPAR1 lysophosphatidic 
acid receptor 1 
-2.96 2.21E-07 3.94E-05 
ADAMTS
1 
ADAM 
metallopeptidase 
with 
thrombospondin 
type 1 motif, 1 
-2.90 6.77E-08 1.56E-05 
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FHL1 four and a half 
LIM domains 1 
-2.82 1.83E-07 3.42E-05 
SDC2 syndecan 2 -2.74 9.42E-09 3.42E-06 
SOX2 SRY (sex 
determining 
region Y)-box 2 
-2.66 3.29E-05 1.92E-03 
IFIT2 interferon-induced 
protein with 
tetratricopeptide 
repeats 2 
-2.60 5.24E-07 1.61E-04 
EHF ets homologous 
factor 
-2.35 1.08E-04 4.72E-03 
CTSH cathepsin H -2.32 2.33E-09 1.12E-06 
KITLG KIT ligand -2.22 4.31E-07 6.74E-05 
ANGPTL
1 
angiopoietin-like 1 -2.18 4.95E-07 7.45E-05 
TLR4 toll-like receptor 4 -2.16 2.96E-06 3.12E-04 
MITF microphthalmia-
associated 
transcription factor 
-2.00 4.36E-05 2.36E-03 
LYN v-yes-1 
Yamaguchi 
sarcoma viral 
related oncogene 
homolog 
-1.99 7.03E-05 3.37E-03 
PAK3 p21 protein 
(CDC42/Rac)-
activated kinase 3 
-1.98 2.15E-06 2.38E-04 
TGFBR2 transforming 
growth factor, 
beta receptor II 
(70/80kDa) 
-1.94 5.07E-05 2.65E-03 
TIAM1 T-cell lymphoma 
invasion and 
metastasis 1 
-1.85 4.27E-06 4.04E-04 
SLC12A2 solute carrier 
family 12 
(sodium/potassiu
m/chloride 
transporters), 
-1.84 9.87E-06 7.50E-04 
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member 2 
WDR44 WD repeat 
domain 44 
-1.82 9.52E-06 7.30E-04 
CTSD cathepsin D -1.75 1.47E-04 5.90E-03 
FGF7 fibroblast growth 
factor 7 
-1.73 8.05E-06 6.43E-04 
STC1 stanniocalcin 1 -1.67 4.01E-02 2.81E-01 
SH3PXD
2B 
SH3 and PX 
domains 2B 
-1.65 1.03E-05 7.77E-04 
RHOU ras homolog 
family member U 
-1.64 9.48E-06 7.30E-04 
CLU clusterin -1.63 1.03E-06 1.34E-04 
S100B S100 calcium 
binding protein B 
-1.62 4.94E-05 2.61E-03 
LGALS3 lectin, 
galactoside-
binding, soluble, 3 
-1.61 1.66E-05 1.12E-03 
FKBP1A FK506 binding 
protein 1A, 12kDa 
-1.60 4.74E-05 2.52E-03 
WWOX WW domain 
containing 
oxidoreductase 
-1.60 3.78E-06 3.74E-04 
CTGF connective tissue 
growth factor 
-1.57 8.06E-05 3.75E-03 
XIAP X-linked inhibitor 
of apoptosis 
-1.55 1.84E-04 7.04E-03 
NOV nephroblastoma 
overexpressed 
-1.54 8.41E-05 3.87E-03 
MET met proto-
oncogene 
(hepatocyte 
growth factor 
receptor) 
-1.53 2.27E-04 8.31E-03 
IFNAR1 interferon (alpha, 
beta and omega) 
receptor 1 
-1.52 5.81E-05 2.92E-03 
AZGP1 alpha-2-
glycoprotein 1, 
zinc-binding 
 
-1.52 5.42E-05 2.78E-03 
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SIM2 single-minded 
homolog 2 
(Drosophila) 
-1.50 2.90E-04 9.76E-03 
WARS tryptophanyl-tRNA 
synthetase 
-1.50 2.04E-05 1.32E-03 
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